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Lymphomas comprise a heterogeneous group of neoplasms that arise in the lymphatic system. 
Lymphomas are classified into Hodgkin and non-Hodgkin lymphomas, and they are further 
categorized into tens of different subtypes. This thesis focuses on two rare lymphoma subtypes: 
nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) and primary mediastinal large B-cell 
lymphoma (PMBCL). Although the majority of lymphomas are sporadic, a familial component has 
been observed in both Hodgkin and non-Hodgkin lymphoma. The aim of this thesis was to study the 
genetic background of familial NLPHL and PMBCL predisposition.  
Hodgkin lymphoma is classified into NLPHL and classical Hodgkin lymphoma (cHL). Germline 
mutations of the KLHDC8B gene have been observed in some families with cHL, implicating a role 
for KLHDC8B in cHL predisposition. We identified a novel Finnish family with four cousins affected 
by NLPHL and collected samples from three previously reported NLPHL families. The KLHDC8B 
gene was analyzed in all four families, but mutations were not detected, suggesting that germline 
mutations of KLHDC8B do not underlie familial NLPHL susceptibility. 
To further clarify the genetic basis of NLPHL predisposition, the Finnish family was studied with new 
genome-wide methods. We genotyped single nucleotide polymorphisms (SNP) in the family 
members, and the SNP data was used for linkage analysis to identify genomic regions segregating 
with NLPHL. In addition, the exome of one NLPHL affected family member was sequenced with 
massive parallel sequencing. Data from these two efforts were combined, and a germline deletion of 
two nucleotides (c.2437-2438delAG) leading to frameshift and premature stop codon was observed in 
the NPAT gene. Subsequently, NPAT was screened in a number of familial and sporadic Hodgkin 
lymphoma cases, and an in-frame deletion of one serine residue was found to be more frequent in the 
cases versus healthy controls (odds ratio 4.11, p = 0.018). Thus, NPAT was identified as a candidate 
gene for NLPHL predisposition. 
The familial risk in NLPHL was studied by using the Finnish Cancer Registry (FCR) and the Finnish 
Population Registries. A keyword-based search was utilized to identify patients with NLPHL 
diagnosis in the FCR, and a family member cohort comprising of the first-degree relatives of 692 
patients was collected. Cancer data for the relatives was derived from the FCR. We calculated the 
standardized incidence ratios (SIRs) for all cancers, non-Hodgkin lymphoma, cHL and NLPHL in the 
family member cohort. The respective SIRs were 1.1 for all cancers, 1.9 for non-Hodgkin lymphoma, 
5.3 for cHL and 26 for NLPHL. In addition, we obtained primary tumor samples from 20 first-degree 
relatives with either NLPHL or other Hodgkin lymphoma diagnosis in the FCR. The samples were 
histopathologically reviewed, and the SIR for NLPHL was also evaluated by accepting only relatives 
with verified NLPHL diagnosis as observed cases. The SIR on the basis of relatives with 
histopathologically verified NLPHL diagnosis was 19. Thus, we observed a high familial risk in 
NLPHL, suggesting that familial factors contribute to NLPHL susceptibility. 
PMBCL is a distinct diffuse large B-cell lymphoma (DLBCL) entity. We studied a family with three 
siblings and a cousin affected by DLBCL. Re-examination of medical records and tumor samples 
revealed that the three siblings had PMBCL and the cousin had extranodal DLBCL. All four tumors 
resembled each other histopathologically, proposing a common background. Genome-wide SNP 
array, linkage analysis and exome sequencing of two of the siblings were performed to identify the 
genetic factor underlying PMBCL/DLBCL in this family. A missense change c.5533C>A 
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(His1845Asn) was detected in the MLL gene and was the only non-database variation residing in 
linked regions and segregating in lymphoma affected family members. A putative domain region 
surrounding the variant was analyzed in a validation set of 106 non-Hodgkin lymphoma cases but 
other mutations were not detected. To our knowledge, this is the first description of familial clustering 
of PMBCL. Our findings suggest that sometimes PMBCL may arise in the context of familial 
predisposition, and MLL was identified as a candidate gene for PMBCL susceptibility. However, our 






Review of the literature 
 
1. Cancer  
1.1 Hallmarks of cancer 
Cancer is a group of different disease entities having a common feature: malignant growth. Cancer 
develops from normal cells which have acquired genetic alterations leading to abnormal cell 
physiology and phenotype. Six biological capabilities essential in tumorigenesis have been proposed 
as the “Hallmarks of Cancer” by Douglas Hanahan and Robert A. Weinberg (Hanahan & Weinberg 
2000, Hanahan & Weinberg 2011). These hallmarks include the ability of cancer cells to maintain 
proliferative signaling (1), to avoid growth suppressors (2) and to escape apoptosis (3). Cancer cells 
have also acquired an unlimited capacity to replicate (4). The last two hallmarks are the formation of 
new blood vessels to sustain tumor growth (5) and the local invasion of cancer cells as well as their 
dissemination to more distant sites (6). More recently, two “Emerging Hallmarks” were suggested to 
be possibly important for the progression of cancer: altered energy metabolism in the cancer cells to 
support active cell proliferation and the capability to avoid destruction by the immune system 
(Hanahan & Weinberg 2011). Genomic instability and tumor growth enhancing inflammation were 
implicated to be important factors underlying the Hallmarks of Cancer (Hanahan & Weinberg 2011, 
Negrini et al. 2010).  
1.2 Histological changes 
In many cancers, the progression from a normal cell to a clinically detectable tumor takes years or 
even decades. This progression can be observed histologically as step-wise changes in the tissue 
morphology and cell phenotype. Minor changes in the tissue architecture include hyperplasia, an 
abnormally large number of cells in a tissue which otherwise appears normal, and metaplasia, 
displacement of normal cells by another cell type which themselves, however, appear normal. In a 
tissue with dysplasia, the individual cells present with atypical features, for example abnormal nuclear 
size and figure, which are detectable by microscope. Benign growth is an expansion of cells which 
can often be detected by eye but does not invade to the nearby tissues. Both dysplasia and benign 
tumors can progress to cancer. (Weinberg 2007 p.34-39).    
1.3 Cancer risk 
The risk of cancer increases with age, and cancer is likely to become an even larger burden for the 
healthcare system, as the age distribution of the population changes particularly in the western world. 
Cancer risk of an individual is also affected by environmental and genetic factors, and the 
combination and interactions of these two (Hemminki et al. 2006). While high-penetrance inherited 
genetic factors play the major role in only a small fraction of cancers, environmental and lifestyle 
factors strongly impact the risk of many common malignancies. For example, tobacco smoking, 
obesity, viral and bacterial infections and occupational exposures increase cancer risk (Peto 2001). In 
a recent study from the United Kingdom, it was estimated that approximately 40% of all cancers in 
2010 were due to 14 environmental or lifestyle factors, and tobacco smoking alone was responsible 
for 19.4 % of cases (Parkin et al. 2011). Table 1 summarizes some common cancers in Finland in 
2009 as well as some of their environmental risk factors.  
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Table 1. Some common cancers in Finland in 2009 (Finnish Cancer Registry, Cancer Statistics at 
www.cancerregistry.fi) and their known environmental risk factors. Data from Peto 2001 and Parkin 
et al. 2011.  
Cancer Primary Site Environmental Risk Factors 
Breast overweight, hormonal factors, inadequate 
exercise, low parity 
Colon and Rectum tobacco, diet*, overweight, inadequate exercise 
Lung tobacco, asbestos, ionizing radiation 
Endometrium overweight, hormonal factors, inadequate 
exercise 
Non-Hodgkin Lymphoma EBV, HIV 
Melanoma UV-radiation 
Pancreas tobacco, overweight 
Ovary hormonal factors 
Kidney tobacco, overweight 
Stomach tobacco, H.Pylori, diet* 
Bladder, Ureter tobacco 
Leukaemia ionizing radiation 
Liver tobacco, HBV, HCV, alcohol 
Cervix uteri tobacco, HPV 
Gallbladder, bile ducts overweight 
Oesophagus tobacco, alcohol, diet*, overweight 
Pharynx, Larynx, Oral cavity tobacco, alcohol, diet* 
*consumption of fibre, salt, meat and fruits and vegetables; EBV, Epstein-Barr virus; HIV, Human 
immunodefiency virus; UV, ultraviolet; H. Pylori, Helicobacter Pylori; HBV, Hepatitis B virus; HCV, Hepatitis 
C virus; HPV, Human papilloma virus. 
The carcinogenic effect of some of the environmental risk factors, such as tobacco and UV-radiation, 
is mediated by causing DNA damage. However, the tumor promoting effect can also result from 
enhanced cell proliferation, for example due to hormonal stimulation, or from chronic inflammation 
caused, for example, by a viral infection (Weinberg 2007 p.439-444). In addition, inherited genetic 
variations modify the individual risk (Hemminki et al. 2006). Treating cancer is expensive and the 
treatments are not always curative, and cancer treatments frequently have side-effects, such as nausea 
and neutropenia. In addition, cancer treatments may predispose to secondary malignancies. Therefore, 
understanding the epidemiology, etiology and the biological processes in cancer is important, to 
develop better strategies to prevent, diagnose and treat cancer.  
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2. Cancer genetics 
The process from a normal cell to cancer, “tumor progression”, has been suggested to follow an 
evolutionary model of carcinogenesis that resembles natural selection (Weinberg 2007 p.413-415). In 
this model, the key step is the acquisition of a genetic alteration which enables a cell to gain growth 
and proliferation advantage. As the cell proliferates, the descendants inherit the advantageous 
genotype and traits, and may form an effectively proliferating clonal population. At some point, a 
descendant cell acquires a second beneficial mutation, resulting in its domination and better survival, 
and thus, the positive selection of this cell and its progenies. As more rounds of clonal expansion 
repeat itself, the cells gradually progress to cancer cells by accumulating several genetic abnormalities 
in their genome, which enable the cells to acquire the phenotypic features and physiological 
capabilities that characterize cancer (Weinberg 2007 p.413-415). In addition to this Darwinian model 
of tumor progression, another model involving cancer stem cells (CSC) has been proposed (Weinberg 
2007 p.416-419). In this model, a small number of self-renewing CSCs with unlimited replicative 
potential produce the cell population in a tumor. Most descendant cells are more differentiated than 
the CSCs and have a limited ability to proliferate. Thus, only genetic alterations occurring in the 
CSCs lead to tumor progression (Weinberg 2007 p.416-419).   
2.1 Mutations in cancer genes  
At present, over 1% of known genes have been implicated in the development of cancer, and 
information on identified cancer genes is being collected and updated by the Cancer Gene Census 
project (Futreal et al. 2004, http://www.sanger.ac.uk/genetics/CGP/Census). According to Futreal et 
al. (2004), about 90% of the cancer genes harbor somatic mutations, 20% have germline mutations 
and 10% show both types of mutations. The causative genetic defects in cancer can be chromosomal 
rearrangements, copy number variations of whole chromosomes or smaller genomic regions, or they 
can be substitutions of single nucleotides, small insertions and deletions of nucleotides, or epigenetic 
changes (McKenna & Roberts 2009, Stratton 2011). Usually more than one genetic change is required 
for cancer development. The mutations providing survival and growth advantage and contributing to 
malignant growth are called “driver mutations”, and they occur in cancer genes. The major part of 
mutations in cancer cell genomes are, however, so called “passenger mutations”, which are incidental 
and do not contribute to tumorigenesis (Greenman et al. 2007, Wood et al. 2007).  
2.2 Oncogenes 
Oncogenes encode proteins that act as transcription factors, chromatin remodelers, growth factors, 
growth factor receptors, signal transducers and apoptosis regulators which contribute to the regulation 
of cell growth, proliferation, and apoptosis (Croce 2008). Proto-oncogenes are normal genes, which, 
when acquiring an activating mutation, become oncogenes that induce cancer development. The gain-
of-function mutations can be mutations of a single nucleotide, larger chromosomal rearrangements 
and amplifications (Croce 2008). Oncogenes are dominantly acting, and thus, mutation of only one 
gene copy of a proto-oncogene is enough for the cancer promoting effect. It has also been suggested 
that non-coding RNAs can act as oncogenes (Chen et al. 2012). 
Common known oncogenes are KRAS, HRAS and NRAS, which are GTPases operating in cellular 
signal transduction pathways (Pylayeva-Gupta et al. 2011). Mutations affecting specific codons in 
these genes of the Ras-family result to constitutive activity of many downstream pathways, eventually 
stimulating cell proliferation, growth and other cancer-inducing processes. Ras-family genes are 
frequently mutated in different types of cancer, and they are highly mutated in pancreatic, colorectal, 
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thyroid and lung cancers (Bos 1989). The oncogenic activation of BRAF is frequently found in 
malignant melanoma and it is most often caused by a missense mutation resulting to V600E amino 
acid substitution, which leads to increased kinase activity and abnormal phosphorylation of target 
proteins (Davies et al. 2002, Wan et al. 2004). Aberrant activation of the MYC gene is common in 
many hematologic malignancies and results from chromosomal rearrangements which combine the 
gene with a translocation partner (Slack & Gascoyne 2011). An oncogenic role has also been 
proposed for the microRNA (miRNA) cluster miR-17-92, which is located in the chromosomal region 
13q31, and increased expression of miRNAs derived from this cluster has been observed in B-cell 
lymphomas (He et al. 2005). 
2.3 Tumor suppressor genes 
Tumor suppressor genes encode proteins which control and restrain cell growth and proliferation. In 
cancer, tumor suppressor genes harbor loss-of-function mutations resulting to lack or ineffectiveness 
of the protein product and leading to dysregulation of growth, proliferation and apoptosis. The 
inactivation of a tumor suppressor gene can derive from missense and truncating mutations, deletions 
and epigenetic silencing (Vogelstein & Kinzler 2004). The “two-hit hypothesis” proposing that 
mutations in both gene copies of a tumor suppressor gene are required for tumorigenesis was first 
introduced by Alfred Knudson in 1971 based on his studies on sporadic and familial retinoblastoma 
(Knudson 1971). He also suggested that in familial cancer cases one allele of a tumor suppressor gene 
is mutated already in the germline and the second, affecting the other allele of the gene, is somatic, 
whereas in sporadic cases both alleles are mutated somatically. Although the “two-hit hypothesis” still 
forms the basis of tumor suppressor genetics, at present it is thought that in addition to the biallelic 
loss-of-function of a tumor suppressor gene, which itself is an important step, other genetic events are 
likely needed for cancer development in both familial and sporadic cancers (Berger et al. 2011). 
Evidence has also emerged in recent years suggesting that haploinsufficiency (defect in only one 
tumor suppressor gene copy) and/or reduced gene dosage may be enough to induce tumorigenesis 
(Berger et al. 2011, Santarosa & Ashworth 2004). In addition, non-coding RNAs, such as miRNAs, 
can function as tumor suppressors for example by targeting proto-oncogenes and suppressing their 
expression (Chen et al. 2012). 
Tumor suppressor genes can be classified into gatekeepers and caretakers (Kinzler & Vogelstein 
1997). The gatekeepers are genes that negatively regulate cell growth and proliferation, and therefore 
inactivation of both alleles directly enhances cancer development. Well-characterized gatekeepers 
include, for example, NF1, SUFU, TP53 and VHL, and inherited loss-of-function mutations in one of 
these genes predispose to specific cancer susceptibility syndromes (Vogelstein & Kinzler 2004). The 
class of caretakers, also called stability genes, comprises of genes whose role is to minimize the 
number of constantly occurring genetic alterations (Vogelstein & Kinzler 2004). The caretakers are 
involved in cellular functions such as DNA repair and control of mitotic recombination, and examples 
of caretaker genes are the mismatch repair (MMR) genes, ATM and BRCA1/2. Biallelic defects in 
caretaker genes contribute to cancer development indirectly, as impaired gene function causes overall 
accelerated mutation rate thus increasing the possibility of a gatekeeper or proto-oncogene acquiring a 
mutation that confers growth advantage. A third group of tumor suppressor genes, “landscapers”, has 
also been suggested (Kinzler & Vogelstein 1998). Defects in landscaper genes promote 
carcinogenesis by causing an abnormal microenvironment which affects the growth and development 
of epithelial cells and increases the possibility of their neoplastic transformation. Let-7 is a negative 




2.4 Cancer genomes 
Genome refers to the entire genetic information of an organism. The Human Genome Project started 
in 1990, and completed the sequencing of the whole human genome in 2003 (International Human 
Genome Sequencing Consortium 2004, Lander et al. 2001, Venter et al. 2001). The human genome 
contains around 21 000 protein coding genes (Clamp et al. 2007) which encompass only about 1.5% 
of the genome. In addition, the human genome encodes non-coding RNAs, which affect functions 
such as protein translation, transcript splicing, mRNA stability, and cell-cycle regulation, and includes 
other types of conserved sequences which are biologically functional, for example regulatory regions 
(Lander 2011). The functional non-coding elements have been suggested to comprise even a larger 
part of the genome than genes (Lander 2011), and a recent study by the ENCODE project consortium 
estimated that altogether 80% of the human genome is involved in biochemical functions (ENCODE 
Project Consortium et al. 2012). However, the ENCODE study was subsequently criticized for 
methology and for their definition of biological function (Doolittle 2013, Graur et al. 2013, Niu & 
Jiang 2013). 
The publicly available data about the human genome and its variations has accelerated the 
development of technologies which enable large-scale and systematic characterization of the genome. 
Single nucleotide polymorphism (SNP) arrays allow the genotyping of millions of variants in the 
genome as well as the detection of copy number variations. The massive parallel sequencing 
technologies now enable the sequencing of the whole genome,  exome or a targeted region of the 
genome, as well as the genome-wide detection of protein-DNA interactions (ChIP-seq) and 
characterization of the transcriptome (RNA-seq) (Martin & Wang 2011, Park 2009, Shendure & Ji 
2008). The transcriptome can also be studied by using gene expression arrays. These new methods are 
valuable for biomedical research, as they largely facilitate the research on how genetic variations 
affect the phenotypic differences between individuals and populations and the risk of various diseases. 
In addition, they enable the genome-wide and systematic characterization of cancer genomes.  
The recent development of massive parallel sequencing technologies has emphasized the role of 
bioinformatics and data processing in cancer genetics. The huge amount of data produced by large-
scale sequencing efforts has created a need for new computational tools and resources (Shanker 
2012). Bioinformatics softwares, programs and algorithms are needed, for example, for the processing 
of raw sequencing data (quality check, read alignment), for the visualization of sequencing data 
(reads), for the detection of single nucleotide variations and structural changes and for the comparison 
of sequence data and genetic databases. In addition, computational tools are required for the 
comparison of tumor genome and germline from the same individual as well as for the analysis of a 
large number of genomes. Increasing amounts of storage space and computational power are also 
needed for the management of sequencing data. 
Some new cancer genes have already been identified by using large-scale sequencing such as 
HOXB13, MLL2 and ARID1A (Ewing et al. 2012, Jones et al. 2010, Morin et al. 2011). Recent studies 
suggest that commonly mutated cancer genes are largely outnumbered by those that are mutated only 
rarely in a particular cancer type (Yates & Campbell 2012). The systematic studies have also provided 
preliminary insight into the ratio of driver to passenger mutations in cancer genomes and into the 
prevalence of somatic mutations in individual tumors and different cancer types. In a resequencing 
study of the coding regions of 518 protein kinase genes, Greenman et al. (2007) estimated that 
approximately 80% of single base substitutions were passenger mutations (Greenman et al. 2007), and 
the larger number of passengers compared with drivers was also suggested by another study 
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characterizing the mutation patterns of the coding parts of the genome in breast and colon cancers 
(Wood et al. 2007).  
The number of both chromosomal abnormalities and single base mutations has been reported to vary 
between cancer types and even between different tumors of the same cancer type (Stratton 2011) 
(Table 2). Melanoma and lung cancer appear to harbor a large amount of mutations across the genome 
and a part of those reflect the effect of exposures to carcinogens such as UV light and tobacco 
(Greenman et al. 2007, Pleasance et al. 2010a, Pleasance et al. 2010b), whereas childhood 
medulloblastoma and acute myeloid leukemia harbor fewer somatic mutations (Mardis et al. 2009, 
Parsons et al. 2011). Whole-genome profiling of cancer by next-generation sequencing efforts have 
also lead to the characterization of “chromothripsis”, a massive genomic rearrangement phenomenon 
involving typically a single or a few chromosomes and present in at least 2-3% of all cancer types 
(Forment et al. 2012, Stephens et al. 2011). Chromothripsis was suggested to occur in a single cellular 
event where a chromosome first shatters into pieces and is subsequently inaccurately repaired by 
cellular machineries, leading to loss of chromosomal material and rearrangements. Despite these new 
advances in the characterization of cancer genomes, more studies with larger sample sets are needed 
to obtain a comprehensive picture of the common patterns of somatic mutations in different cancers. 
For this purpose, international consortiums such as the International Cancer Genome Consortium, 
which plans to characterize the genomes of 50 common cancers, has been established (International 




Table 2. The number of somatic non-silent sequence variations in the coding parts of the genome in 
different cancer types detected in large scale sequencing studies. Missense, nonsense, splice site, in-
frame indels and frameshift mutations are included.  
Cancer Number of mutations per case Reference 
Childhood medulloblastoma 8 
(average from 22 tumors) 
(Parsons et al. 2011) 
Acute myeloid leukaemia 12 
(1 tumor) 
(Mardis et al. 2009) 
Diffuse large B-cell lymphoma 5-29 
(6 tumors) 
(Pasqualucci et al. 2011) 
Ovarian cancer 47 
(average from 316 tumors) 
(Cancer Genome Atlas 
Research Network 2011) 
Hepatocellular carcinoma 72 
(1 tumor) 
(Totoki et al. 2011) 
Small cell lung cancer 105 
(1 cell line) 
(Pleasance et al. 2010b) 
Colorectal cancer 49-111 
(11 tumors) 
(Wood et al. 2007) 
Breast cancer 38-193 
(11 tumors) 
(Wood et al. 2007) 
Melanoma 194 
(1 tumor) 
(Pleasance et al. 2010a) 
 
2.5 Inherited cancer susceptibility 
Inherited cancer susceptibility syndromes are characterized by a highly increased lifetime risk of 
cancer, and they often display an autosomal dominant mode of inheritance (Nagy et al. 2004). 
Although cancer susceptibility syndromes are rare, together they have been estimated to account for 
5-10% of cancer. The clinical clues indicating an inherited cancer predisposition include an early age 
of cancer onset, several relatives with the same cancer type and multiple primary tumors in the same 
individual. In addition to cancer, the affected family members may present with other features 
associated with the susceptibility syndrome, such as benign tumors or skin lesions. More than 200 
cancer susceptibility syndromes and about 100 underlying genes have been described (Cazier & 
Tomlinson 2010, Nagy et al. 2004). A heritable form is known for the majority of cancers, however, 
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in carcinomas of the lung and cervix uteri and malignancies of the hematopoietic system the incidence 
of dominantly inherited susceptibility is very low (Knudson 2002). 
The inherited predisposition to cancer is due to a mutation in the germline. However, additional 
somatic mutations are required for carcinogenesis. Most of the genes harboring germline mutations 
that predispose to cancer are tumor suppressors (Knudson 2002) and examples of such genes are the 
RB1, TP53, BRCA1, BRCA2 and the MMR genes. Germline mutations in RB1 predispose to unilateral 
and bilateral retinoblastomas, whereas TP53 is mutated in Li-Fraumeni syndrome, a familial cancer 
syndrome with susceptibility to breast cancer, sarcoma, leukaemia and brain tumors 
(http://www.ncbi.nlm.nih.gov/omim). Mutations in the caretakers BRCA1 and BRCA2 and the MMR 
genes underlie the common familial cancer syndromes, hereditary breast and ovarian cancer and the 
Lynch syndrome (Garber & Offit 2005). A few cancer syndromes are caused by mutations in 
oncogenes, such as RET in multiple endocrine neoplasia type 2 and KIT in hereditary gastrointestinal 
stromal tumor syndrome (Knudson 2002), and some syndromes are inherited in a recessive manner, 
for instance, ataxia-telangiectasia, caused by mutations in the ATM (Garber & Offit 2005). 
Traditionally, high risk cancer susceptibility genes have been identified by studying families with 
cancer predisposition by utilizing linkage analysis, positional cloning and candidate gene approaches. 
More recently, exome and whole genome sequencing have enabled the identification of new 
susceptibility genes for familial cancer. Well-known cancer susceptibility syndromes and respective 
susceptibility genes are listed in Table 3. 
Familial clustering of cancer can also occur outside the context of established high risk cancer 
syndromes. Heritable factors have been estimated to have significant effect on the risk of prostate 
cancer, colorectal cancer and breast cancer (high heritability) even though only a small proportion is 
explained by high risk susceptibility genes (Lichtenstein et al. 2000). Indeed, much of the familial 
occurrence of common cancers and inherited cancer risk has been suggested to result from the 
combination of low and moderate penetrance genetic factors, which contribute to an individual’s 
cancer risk but do not cause cancer syndromes inherited in a Mendelian pattern (Cazier & Tomlinson 
2010, Fletcher & Houlston 2010). In breast cancer, moderate risk alleles in CHEK2, ATM, BRIP1 and 
PALB2 genes confer a 2-3-fold risk of breast cancer, and in colorectal cancer heterozygous mutations 
in MUTYH and a specific mutation in APC have been associated with increased cancer risk (Foulkes 
2008). The low penetrance variants associated with cancer risk are thought to be common and to 
usually confer a 1.1-1.6-fold cancer risk, and they can be detected with genome-wide association 
studies (GWAS), usually in unselected/sporadic cases (Fletcher & Houlston 2010). In addition, in 
complex and polygenic diseases gene-gene interactions (epistasis) have been suspected to play a role 
and to explain a part of the “missing heritability” (Ritchie 2011). Thus, an individual’s cancer risk 
may be largely affected by the combination of moderate and low penetrance risk alleles. At present, 
however, genotyping of the known low and moderate penetrance variants to estimate an individual’s 









Table 3. Some well-known inherited cancer susceptibility syndromes. Data from Garber & Offit 2005 
and http://www.ncbi.nlm.nih.gov/omim. 
Syndrome  Mode of 
Inheritance 
Susceptibility gene(s) Most common cancers 
Lynch syndrome Autosomal 
dominant 









BRCA1, BRCA2 Breast cancer, ovarian 






Li-Fraumeni syndrome Autosomal 
dominant 
p53, CHEK2 Breast cancer, 
sarcomas, leukemia, 
brain tumors 
Peutz-Jeghers syndrome Autosomal 
dominant 
STK11 Colon cancer, breast 






VHL Renal cell cancer 
Multiple endocrine 
neoplasia 2 syndrome 
Autosomal 
dominant 
RET Medullary thyroid 
cancer 
Familial gastrointestinal 





Ataxia-telangiectasia Autosomal recessive ATM Lymphoma, leukemia, 
solid tumors 
Bloom syndrome Autosomal recessive RECQL3 Leukemia, other 
malignancies 
Xeroderma pigmentosum Autosomal recessive XPA-G, POLH Skin cancer, leukemia, 
melanoma 









3. The lymphatic system 
The lymphatic system is an important part of the immune system. It consists of lymphatic organs 
which include spleen, thymus and lymph nodes and of lymphatic tissue which is associated with other 
organs, such as mucosa-associated lymphatic tissue, lymphatic tissue of the bone marrow and 
lymphatic nodules located in the alimentary and respiratory systems (Figure 1). In addition, 
superficial and deep lymphatic vessels enable the circulation of lymphatic cells and lymph which 
brings large molecules, for example antigens, from peripheral tissues to lymph nodes. The lymphatic 





The cellular component of the lymphatic system is composed of three types of lymphocytes, B-cells, 
T-cells and Natural Killer (NK) cells and supporting cells. The lymphatic cells express unique cluster 
of differentiation (CD) molecules on their surface, and visualization of the CD markers with 
immunohistochemical methods can be used to classify subtypes of lymphatic cells. The CD markers 
can be expressed either constantly during the cell’s whole life or only in a specific phase of 
differentiation or cell activation.  
The stem cells for T and B lymphocytes are produced in the bone marrow. However, the antigen-
independent differentiation of T-cells takes place in the thymus whereas B-cells differentiate in the 
bone marrow and gut-associated lymphatic tissue. During the differentiation process, the 
lymphocytes become genetically programmed and learn to recognize a specific antigen before they 
enter the circulation or lymph. The antigen-dependent activation of lymphocytes occurs in lymph 
nodes and other secondary lymphatic organs as the result of encountering the specific antigen, and 
leads to the formation of effector and memory cells. The structure and cells of the lymphatic system 
have been reviewed in Ross & Pawlina 2011 p.440-445, 453.  
Figure 1. Components of the lymphatic system: 
the lymphatic organs, lymphatic tissue and 
lymphatic vessels. Reprinted with permission 
from Cancer Research UK website 




Table 4. Characteristics and activation mechanisms of T and B lymphocytes. Data from Ross & 
Pawlina 2011 p.444, 448-451 
Lymphocyte Immunophenotype Activation Function after 
activation 








T-cell markers and 
CD4+ 
Recognition of foreign 
peptides bound to 
MHC II molecules on 









T-cell markers and 
CD8+ 
Recognition of foreign 
peptides bound to 
MHC I molecules on 
the surface of cells 
Destroy the host cell 
B-cells CD9+, CD19+, 
CD20+, BCR+ 
Binding of antigen to 






plasma or memory 
cells 
Produce antibodies 
BCR, B-cell receptor; TCR, T-cell receptor; MHC, Major histocompatibility complex  
 
3.2 Antibodies and B-cell development 
Practically all Hodgkin lymphomas and approximately 80-90% of non-Hodgkin lymphomas originate 
from B-cells (Ruutu et al. 2007, p. 393 and 434). B-cells produce antibodies, or immunoglobulins, 
which are antigen-binding molecules. Antigen-specific immunoglobulins are present on the surface of 
a mature B-cell and function as B-cell receptors (BCR). B-cells, depending on their phase of 
development, can also secrete soluble versions of the immunoglobulin molecule into the extracellular 





The immunoglobulins consist of two identical heavy chains and two identical light chains (Figure 2). 
Each chain includes a variable domain with three hypervariable regions. The hypervariable regions of 
one heavy and one light chain form a unique binding site for a specific antigen. The class of the 
immunoglobulin molecule is determined by the constant domains of the heavy chain, and there are 
five different classes: IgA, IgM, IgD, IgE and IgG. The immunoglobulin class affects the antibody 
function and regulates which cells are activated by the antibody-antigen complex.  
During B-cell development in the bone marrow and gut-associated lymphatic tissue, the BCRs are 
formed from genes encoding the proteins in the heavy and light chains of the molecule so that a vast 
repertoire of B-cells recognizing different antigens is produced. The process underlying the formation 
of B-cell diversity is the occurrence of recombination events, which result in different combinations 
of V-, D- and J-genes encoding the variable region in heavy chains and V- and J-genes which encode 
the variable region in light chains. The constant domains are encoded by a gene representing the IgM 
type of immunoglobulin. After the formation of a functioning BCR receptor, the B-cells are tested in 
the bone marrow and cells reacting with the individual’s own molecules are destroyed. Before 
entering the circulation, the surviving B-cells acquire also an IgD type of BCR on their cell surface.  
The mature B-cells circulate mainly in the secondary lymphoid organs, and the activation of a B-cell 
is initiated by the binding of an antigen to the BCR. An efficient activation usually also requires 
stimulation from the helper T lymphocytes. The activated B-cell undergoes proliferation creating a 
group of daughter cells expressing a BCR identical to the parent cell, a phenomenon called “clonal 
expansion”. The proliferation leads to the development of a germinal center (GC) where the affinity 
of the antigen-binding site is modified in a process called “somatic hypermutation”. In this process, 
the antigen-binding regions of the gene encoding the V domain of the antibody molecule acquire 
point mutations, eventually resulting to immunoglobulin molecules with improved affinity for the 
antigen. In addition, signals from the helper T-cells contribute to the initiation of a process called 
“class switching”, where due to recombinations, the VDJ-genes encoding the immunoglobulin’s 
variable domain are combined the constant domains representing IgG, IgA or IgE.  
After the somatic hypermutation and class switching processes, a part of the B-cells differentiate into 
plasma cells, which secrete soluble antibodies into extracellular fluids. Although most plasma cells 
Figure 2. The basic structure of IgG 
immunoglobulin. H refers to heavy 
chain and L refers to light chain. C 
refers to constant domain and V 
refers to variable domain. CDR 
refers to complementarity-
determining regions, also called 
hypervariable regions. Reprinted 
from Sharkey & Goldenberg 2006, in 
CA: Cancer Journal for Clinicians. 
Permission from John Wiley and 




die within two weeks, some of the cells stay alive a long time and continue producing small amounts 
of the antibody. B-cells can also differentiate into memory B-cells. Memory B-cells are characterized 
by the ability to respond quickly to the encounter with their antigen. In addition, the number of 
memory B-cells recognizing a specific antigen is usually higher than the number of respective mature 
B-cells, and the immunoglobulins produced by memory B-cells are mostly IgG or IgA type, which 
mediate to a more “cost-effective” immune response than IgM-type molecules. The somatic 
hypermutation, class switching and differentiation processes underlie the development of 
“immunological memory”, which means that the body’s secondary immune response is more rapid 
and effective than the primary response. However, the high proliferation activity and the large 
number of mutational events can also result in translocations or other genetic variations that lead to 
the development of hematologic malignancies. The structure and function of antibodies, B-cell 
development, somatic hypermutation and class switch recombination have been reviewed in: Hedman 
et al. 2011 p.114-118, p.130-133, Gatto & Brink 2010, Stavnezer et al. 2008, and Teng & 
Papavasiliou 2007. 
 
4. Classification of lymphomas 
Lymphomas are classified into Hodgkin (HL) and non-Hodgkin (NHL) lymphomas. HL is classified 
into two different disease entities, classical HL (cHL) and nodular lymphocyte predominant HL 
(NLPHL). In addition, four subtypes of cHL have been distinguished: nodular sclerosis (NSCHL), 
mixed cellularity (MCCHL), lymphocyte-rich (LRCHL) and lymphocyte-depleted (LDCHL). NHL is 
classified into precursor lymphoid neoplasms, mature B-cell neoplasms and mature T- and NK-cell 
neoplasms. (Swerdlow et al. 2008 p.157-319).  
The most common types of NHL are follicular lymphoma and diffuse large B-cell lymphoma 
(DLBCL). DLBCL can be further classified into different variants, subtypes and distinct large B-cell 
lymphoma entities (Swerdlow et al. 2008 p.234). DLBCL not otherwise specified (NOS) contains the 
molecular subgroups germinal centre B-cell-like (GBC) and activated B-cell-like (ABC) and the 
immunohistochemical subgroups CD5-positive DLBCL, germinal centre B-cell-like and non-germinal 
centre B-cell-like. The common morphologic variants of DLBCL NOS are centroblastic DLBCL, 
immunoblastic DLBCL and anaplastic DLBCL. T-cell/histiocyte-rich large B-cell lymphoma 
(TCRBCL), DLBCL of the central nervous system and primary cutaneous DLBCL, leg type, are 
considered specific DLBCL subtypes. Primary mediastinal large B-cell lymphoma (PMBCL), 
intravascular large B-cell lymphoma, DLBCL associated with chronic inflammation, lymphomatoid 
granulomatosis, ALK-positive large B-cell lymphoma, plasmablastic lymphoma, large B-cell 
lymphoma arising in HHV8-associated multicentric Castleman disease and primary effusion 
lymphoma are considered distinct large B-cell lymphoma entities (Swerdlow et al. 2008 p.234). Table 











Table 5. The World Health Organization classification of lymphomas. Data from Swerdlow et al. 
2008 p.11-12, 179 and 234. 



















Mature B-cell neoplasms 
Chronic lymphocytic leuk. 
B-cell prolymphocytic leuk. 
Splenic marginal zone lymph. 
Hairy cell leukaemia 
Splenic B-cell lymph/leuk 
Lymphoplasmocytic lymphoma 
Heavy chain diseases 
Plasma cell neoplasms  
MALT lymphoma 
Nodal marginal zone lymphoma 
Follicular lymphoma 
Primary cutaneous follicle 
centre lymphoma 
Mantle cell lymphoma 
DLBCL, NOS 
Primary mediastinal large B-cell 
lymphoma  




Mature T-cell neoplasms 
T-cell prolymphocytic leukaemia 
T-cell LGL-leukaemia 
EBV-positive T-cell 
lymphoproliferative disease of 
childhood 
Adult T-cell leukaemia/lymphoma 
Extranodal T-cell lymph, nasal type 
Enteropathy-associated T-cell lymph 
Hepatosplenic T-cell lymphoma 




Peripheral T-cell lymphomas 
Angioimmunoblastic T-cell 
lymphoma 
Anaplastic large cell lymphoma 
 
Leuk, leukaemia; lymph, lymphoma; MALT, extranodal marginal zone lymphoma of mucosa-
associated lymphoid tissue; DLBCL, diffuse large B-cell lymphoma; NOS, not otherwise specified. 
 
5. Hodgkin lymphoma 
Hodgkin lymphoma, previously also known as Hodgkin’s disease, was named according to Thomas 
Hodgkin who in 1832 reported a series of seven patients with lymph node swelling (Hodgkin 1832). It 
is now known that HL is a malignancy of the lymphatic system in which the large neoplastic Hodgkin 
and Reed-Sternberg (HRS) or lymphocyte predominant (LP) cells originate from germinal center B-
cells, and the global incidence of HL is about 3/100 000 per year (Kuppers 2009). HL accounts for 
about 30% of lymphomas, although in Finland the proportion is only 10% (Swerdlow et al. 2008 
p.322, Finnish Cancer Registry, Cancer Statistics at www.cancerregistry.fi).  
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In Finland, approximately 100-120 new cases are diagnosed every year, and both in Finland and 
worldwide NSCHL is the most common HL subtype (Finnish Cancer Registry, 2011). In the recent 
World Health Organization Classification of Tumours of Haematopoietic and Lymphoid tissues 
NSCHL was estimated to account for 70%, MCCHL for 20-25%, LRCHL for 5% and LDCHL for < 
1% of cHL. NLPHL represents about 5% of HL cases (Swerdlow et al. 2008, p.323-334). Most 
patients presenting with HL are young adults and their symptoms commonly include 
lymphadenopathy in the cervical, supraclavicular or axillary lymph nodes. Hodgkin lymphoma is one 
of the success stories of modern oncology, as nowadays the majority of patients can be curatively 
treated (Ruutu et al. 2007 p. 397-401).  
5.1 Epidemiology and risk factors 
Although the exact causes of HL are largely unclear, epidemiological studies have suggested that 
some infections, immune deficiencies and inherited factors all contribute to the risk of HL. In 
addition, some epidemiological features, such as the age and sex distribution of patients, the presence 
of Epstein-Barr virus and geographical incidence patterns are different depending on the HL subtype. 
As the classical subtype of HL accounts for 90-95% of HL, observations from epidemiological studies 
including all HL subtypes represent mainly cHL, particularly NSCHL. (Reviewed in Cartwright & 
Watkins 2004 and Swerdlow et al. 2008 p.323-334). 
Classical HL is characterized by a bimodal age-specific incidence curve with highest peaks in young 
adults (15-35 years) and in the elderly (>60 years) whereas most patients presenting with NLPHL are 
30-50 years old. In NSCHL both males and females are equally affected whereas other cHL subtypes 
and NLPHL are characterized by a male predominance. In developed countries NSCHL is the most 
common HL subtype while in developing countries MCCHL and LDCHL are more frequent. 
MCCHL and LDCHL are also most often associated with HIV infection. (Swerdlow et al. 2008 
p.323-334).  
In space-time clustering studies on HL, clustering of cases in certain areas or places has been 
constantly reported suggesting a role for environmental factors, such as infections and/or exposures, 
in the etiology of HL (Reviewed in Cartwright & Watkins 2004). Positive correlations have been 
reported between HL risk and higher socio-economic status particularly in early childhood (Alexander 
et al. 1991, Gutensohn & Cole 1981). Some studies have reported higher HL risks in occupations with 
frequent exposures to infections, such as teachers and physicians, however, some studies have not 
observed such association (Fonte et al. 1982, Grufferman et al. 1976, Matanoski et al. 1975, Vianna 
et al. 1974). Smoking is associated with a slightly increased risk of HL whereas alcohol consumption 
is associated with a reduced risk (Sergentanis et al. 2012, Tramacere et al. 2012).  
Infectious etiology of HL is consistent with many epidemiological observations, such as the bimodal 
incidence pattern, geographical differences in the age-of-onset of young patients and HL association 
with socio-economical status, family structure and birth order as well as the increased HL risk in 
immune-deficient persons (Reviewed in Hjalgrim & Engels 2008). EBV is the best documented 
infectious agent associated with HL, although it is found in only a part of cHL cases and practically 
never in NLPHL (Swerdlow et al. 2008 p.323-334). The epidemiological behavior of EBV resembles 
HL, elevated antibody titres to EBV-viral capsid antigens have been reported in HL patients, and 
infectious mononucleosis has been associated with an elevated risk of EBV-positive HL (Alexander et 
al. 1995, Hjalgrim et al. 2007, Hjalgrim & Engels 2008). EBV can be detected in the HRS cells, and 
the viral genome has been demonstrated to be monoclonal (Gulley et al. 1994, Weiss et al. 1987). In 
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HIV-infected HL patients, EBV co-infection is present in almost all cases (Herndier et al. 1993). In 
EBV-negative HL cases, the underlying infectious agents, if existing, remain to be characterized.  
A number of genetic association studies, including GWA studies, have aimed to identify genomic risk 
loci associated with HL. Association of the major histocompatibility complex/human leukocyte 
antigen (HLA) region in 6p21 with HL has been frequently observed (Enciso-Mora et al. 2010, 
Diepstra et al. 2005, Klitz et al. 1994, Moutsianas et al. 2011, Urayama et al. 2012). In particular, 
markers in the class II region have been associated with early-onset HL, NSCHL subtype and EBV-
negative HL (Cozen et al. 2012, Klitz et al. 1994, Moutsianas et al. 2011, Urayama et al. 2012), 
whereas HLA class I association with EBV-positive HL and HLA class III association with EBV-
negative HL have been reported (Diepstra et al. 2005, Urayama et al. 2012). Other genomic loci 
associated with HL include 2p16.1 (candidate gene REL), 8q24.21 (candidate gene PVT1) and 10p14 
(candidate gene GATA3) (Enciso-Mora et al. 2010). In addition, polymorphisms in IRF4 and IL6 have 
been suggested to possibly influence HL susceptibility (Broderick et al. 2010, Cozen et al. 2004, 
Liang et al. 2009).  
5.2 Classification, clinical and histopathological features and treatment of Hodgkin lymphoma 
The classification of HL into different subtypes is based on clinical features of the patient and 
morphology and immunophenotype of the tumor. It is common for all HL subtypes that the malignant 
and monoclonal HRS or LP cells comprise only a small fraction of the tumor tissue (approximately 
0.1-10%) whereas most of the tumor consists of polyclonal, benign inflammatory cells (Swerdlow et 
al. 2008 p.327). Clinical staging of the disease is important when planning therapy and the staging of 
HL is based on Ann Arbor/Cotswolds classification (Table 6). In addition to clinical staging, therapy 
decisions are guided by the presence of additional risk factors, which are B symptoms (fever, night 
sweating and weight loss), bulky disease (tumor diameter >10 cm), sedimentation rate and the 
involvement of multiple lymph node regions (Ruutu et al. 2007 p.399-404). As the prognosis of HL is 
good and as many patients are young adults, it is important to choose the least toxic yet efficient 
treatment strategy for each patient group so that the occurrence of complications, such as cardiac 
diseases/mortality, acute toxicity as well as secondary malignancies, can be minimized (Eichenauer & 
Engert 2012). 
Table 6. The Ann Arbor/Costswolds classification of Hodgkin lymphoma. Carbone et al. 1971, Lister 
et al. 1989. 
Stage Description 
I  Single lymph node region or lymphoid structure involvement 
II Lymphoma in two or more lymph node regions or structures on the same 
side of the diaphragm  
III 
 
   III1 
   III2 
Lymphoma in two or more lymph node regions or structures on both sides 
of the diaphragm 
involvement of splenic, celiac, hilar or portal nodes 
involvement of para-aortic, iliac or mesenteric nodes 




5.2.1 Classical Hodgkin lymphoma 
The most common clinical manifestations of cHL include lymphadenopathy and local symptoms 
caused by the tumor mass. Approximately 40% of patients present with B symptoms. The most 
frequently involved lymph node regions are cervical, axillary, mediastinal and para-aortic regions, and 
about 60% of patients have a localized disease. Primary extranodal cHL and mesenteric involvement 
are rare in all cHL subtypes, but MCCHL displays abdominal and splenic involvement more often 
than NSCHL at the time of diagnosis, whereas NSCHL accounts for the majority of mediastinal cHL 
cases. (Swerdlow et al. 2008 p.326-327).  
In Finland, patients with a localized disease are usually treated with ABVD (adriamycin, bleomycin, 
vinblastine, dacarbazine) chemotherapy and local involved field radiotherapy (20-30 Gy) (Ruutu et al. 
2007 p.402-403). This approach is considered least toxic, and is the standard of care for early 
favorable HL also in many other countries (Eichenauer & Engert 2012). For patients with an 
advanced disease (stage III-IV), different combinations of chemotherapy (usually 6-8 cycles) can be 
used, and most commonly used protocols are ABVD and BEACOPP (bleomycin, etoposide, 
adriamycin, cyclophosphamide, vincristine, procarbazine, prednisone). Chemotherapy is typically 
followed by radiotherapy (Eichenauer & Engert 2012). The survival in HL has increased significantly 
in the recent years, but the prognosis is clearly poorest in elderly patients (Sjoberg et al. 2012). In the 
U.S., the 5-year survival in HL was about 85% in 2000-2004 (Brenner et al. 2008) and in Finland the 
5-year survival is over 90% (Finnish Cancer Registry, Cancer Statistics at www.cancerregistry.fi).   
In cHL the large, malignant HRS cells are in the majority of cases derived from B-cells (Swerdlow et 
al. 2008 p.326-334). The Hodgkin cells are mononuclear and the Reed-Sternberg cells multinuclear 
and they reside in the background infiltrate of lymphocytes, eosinophils, histiocytes, plasma cells and 
neutrophils. T lymphocytes are the most numerous reactive cell population in cHL (Schmitz et al. 
2009b). The further classification of cHL into subtypes is based on the features of the 
microenvironment and somewhat on the morphology of the HRS cells: NSCHL is characterized by 
fibrotic collagen bands which surround nodules and by lacunar variants of the HRS cells. In MCCHL 
the lymph node architecture is mostly destroyed, and the collagen bands typical in NSCHL are not 
detected. LRCHL often displays a nodular, but sometimes also diffuse, growth pattern, and can be 
mistaken for NLPHL if immunophenotyping is not used. The HRS cells are mostly present in the 
nodules and neutrophils and eosinophils are usually absent from the background infiltrate. In LDCHL 
the ratio of HRS cells to background lymphocytes is higher than in other subtypes (Swerdlow et al. 
2008 p.322-334).  
The immunophenotype of HRS cells is similar in all cHL subtypes. HRS cells are CD30 and CD15 
positive, but CD20 is not abundantly expressed. HRS cells are usually negative for the transcription 
factors OCT-2, BOB1 and PU.1. EBV-positive HRS cells express LMP1 and EBNA-1. 
Differentiating cHL from large B-cell lymphoma with anaplastic morphology and CD30 expression 
can be problematic, and cHL, particularly NSCHL, can also share features with PMBCL. (Swerdlow 
et al. 2008 p.326-328). 
5.2.2 Nodular lymphocyte predominant Hodgkin lymphoma 
Most patients with NLPHL present with a localized stage I or II disease usually manifesting as 
peripheral lymphadenopathy (Lee & LaCasce 2009). In addition, mediastinal, bone marrow and 
extranodal involvement are uncommon and there is a lower occurrence of additional HL risk factors 
than in cHL. NLPHL is more indolent than cHL and has a better prognosis, thus, less aggressive 
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therapies are recommended for early stage disease in order to reduce complications of the treatment 
(Nogova et al. 2008). In Finland, patients with a localized disease (stage I or II) and without 
additional risk factors are usually treated with involved field radiotherapy (30 Gy) (Ruutu et al. 2007 
p.404). This approach is also internationally recommended for early favorable/early stage NLPHL 
(Chen et al. 2010, Eichenauer & Engert 2012). NLPHL patients with risk factors and patients with an 
advanced disease are treated similarly to cHL, that is, with the combination of chemotherapy and 
radiotherapy (Eichenauer & Engert 2012, Ruutu et al. 2007 p.404). Relapsed NLPHL can be treated 
with high-dose chemotherapy and allogeneic stem cell transplantation, or alternatively, with 
rituximab, a monoclonal anti-CD20 antibody which is currently being investigated as a treatment 
option in NLPHL (Eichenauer & Engert 2012, Maeda & Advani 2009). In many studies, almost 90-
100% of patients achieve remission with the first-line therapy, and although relapses occur in about 
10-35% of cases, the overall 10-year survival in NLPHL is close to 90% (Biasoli et al. 2010, Lee & 
LaCasce 2009). However, late and multiple relapses are common in NLPHL (Lee & LaCasce 2009). 
In a fraction of patients with NLPHL, the disease can transform to a more aggressive lymphoma type, 
most often DLBCL (Al-Mansour et al. 2010, Biasoli et al. 2010).  
The neoplastic cells in NLPHL, LP cells, are variants of the HRS cells, and they are thought to 
originate from germinal-centre B-cells. The LP cells are large, usually mononuclear cells, and the 
nucleus is multilobated. The LP cells reside in a lymphocyte and histiocyte rich infiltrate showing a 
nodular pattern. The microenvironment in NLPHL is characterized by spherical networks formed by 
follicular dendritic cells and the majority of the lymphocytes in the background infiltrate are B cells. 
Neutrophils, plasma cells and eosinophils are uncommon in the infiltrate. In almost all cases, the LP 
cells express the B-cell markers CD20 (Figure 3), CD79a, BCL6 and AID, the B-cell associated 
transcription factors OCT-2, and BOB1 as well as immunoglobulins. In contrast to HRS cells, the LP 
cells are negative for CD15 and CD30 (Figure 3). Typically, the LP cells are surrounded by CD3 and 
CD57 positive T-cell rosettes (Figure 3). Differential diagnoses include TCRBCL and LRCHL. 
(Swerdlow et al. 2008 p.323-325).  
5.2.3 Complications in the treatment of Hodgkin lymphoma 
In the treatment of HL, the acute complications include nausea and neutropenia, and the latter can 
predispose to severe and potentially fatal infections, such as pneumonia and sepsis. Sometimes 
anemia can occur. Chemotherapy often causes alopecia, and some chemotherapeutic agents can cause 
peripheric neuropathy (Ruutu et al. 2007, p.406). The treatment of HL predisposes to secondary 
malignancies, which are the most common cause of death in HL survivors (Darrington & Vose 2012). 
Radiotherapy increases the risk of breast cancer, particularly in young women, and the risk of lung 
cancer is increased in patients who have received radiation therapy and chemotherapy. In addition, the 
risk of gastrointestinal cancers is slightly increased (Darrington & Vose 2012). Some chemotherapies 
cause infertility (Ruutu et al. 2007, p. 407). Other late complications include cardiac morbidity and 
mortality (coronary artery disease, pericarditis, cardiomyopathy, valvular and conduction defects), 
endocrine dysfunction such as thyroid diseases, pulmonary disease and cerebrovascular disease. 
Appropriate screening, such as laboratory tests, mammogram and echocardiogram should be offered 





Figure 3. Hematoxylin and eosin (HE), CD20, CD30 and CD3 stained sections from NLPHL tumor 
biopsies. The LP cells are large atypical cells, comprising only a small fraction of the tumor tissue. 
The LP cells stain positively with CD20 and, in addition, many of the small lymphocytes in the 
background infiltrate are CD20 positive. In contrast, neither the LP cells nor the infiltrating benign 
cells express CD30. The LP cells are often surrounded by CD3-positive T-lymphocytes which form 
“rosettes” around the LP cells. The images were captured with Leica DM LB research microscope 
using 20x and 40x magnification. 
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5.3 Molecular background 
5.3.1 Classical Hodgkin lymphoma 
The HRS cells display a heterogeneous immunophenotype, and the immunophenotype can vary both 
in different tumors as well as in different cells of a particular tumor (Schmitz et al. 2009b). In 
addition, their gene expression profile and phenotype is not similar to any normal cell of the 
hematopoietic system (Schwering et al. 2003). It is now established that the HRS cells originate from 
mature germinal centre B-cells, as they harbor clonal Ig VH and VL rearrangements and as, in the 
majority of cases, the IgV-region genes seem to have undergone somatic hypermutation (Kanzler et 
al. 1996, Kuppers et al. 1994, Marafioti et al. 2000). However, the HRS cells have largely lost the B-
cell specific gene expression but have acquired the ability to express markers of other hematopoietic 
lineages (Schwering et al. 2003, Schmitz et al. 2009b). In addition, the Ig gene transcription is 
compromised in HRS cells, likely due to downregulation of B-cell specific transcription factors and 
epigenetic silencing (Stein et al. 2001, Ushmorov et al. 2004).  
Constitutive activation of nuclear factor-kappa B (NF-κB) transcription factors and the aberrant 
regulation of their target genes in HRS cells have been suggested to play a central role in the 
pathogenesis of cHL. It has been demonstrated that the abnormal functions of the NF-κB pathway 
lead to promoted tumor growth and up-regulation of antiapoptotic proteins, and that blocking NF-κB 
activity inhibits the growth of HRS cells and sensitizes them to apoptosis (Bargou et al. 1997, Hinz et 
al. 2001). In addition, cytokine expression is thought to be essential for the recruitment of the benign 
cell populations in HL, and NF-κB interacts with the Janus kinase/signal transducer and activator of 
transcription (JAK/STAT) pathway which is involved in cytokine signaling (Reviewed in Schmitz et 
al. 2009b). NF-κB up-regulates STAT5, which is overexpressed in many HRS cells (Hinz et al. 2002) 
and whose overexpression has been shown to result in immortalization and HRS cell-like gene 
expression profile in primary B-cells (Scheeren et al. 2008). STAT3 and STAT6 activation have also 
been reported in HRS cells; the activation of the first-mentioned is regulated by several different 
cytokines whereas in the latter IL-13 has been suggested to be the main regulator in HRS cells (Kube 
et al. 2001, Skinnider et al. 2002). NF-κB also cooperates with the transcription factor AP-1 whose c-
Jun and JunB components are constitutively expressed in HRS cells; of these, JunB is directly 
activated by NF-κB (Mathas et al. 2002). The AP-1 activation has been suggested to support 
proliferation of the HRS cells. Factors underlying the NF-κB activity in HRS cells likely include the 
expression of molecules of the tumor necrosis factor receptor family (such as CD30, CD40 and 
RANK), LMP1 (only in EBV
+
 cases), TACI and BCMA receptors and activated Notch1 signaling 
(Chiu et al. 2007, Jundt et al. 2002, Reviewed in Schmitz et al. 2009b).  
The HRS cells have also been shown to aberrantly express some receptor tyrosine kinases (RTKs), 
which, in normal cells, contribute to the regulation of cell growth, differentiation and survival 
(Kuppers 2009). The RTKs expressed by the majority of studied HRS cells but not normal B-cells 
include PDGFRA, DDR2, EPHB1, RON, TRKA and TRKB; however, activating mutations 
underlying this finding were not detected (Renne et al. 2005b). The coexpression of multiple RTKs 
was subsequently suggested to be mostly associated with EBV
- 
cHL cases (Renne et al. 2007). Other 
abnormally active pathways in HRS cells include the mitogen-activated protein kinase/extracellular 
signaling regulated kinase (MAPK/ERK) pathway, a pathway regulating cell survival and 
proliferation, and the phosphatidylinositol 3-kinase/Akt kinase pathway, where the activated Akt 
promotes cell survival by phosphorylating its downstream targets (Dutton et al. 2005, Zheng et al. 
2003). In addition, a recent global expression study on microdissected HRS cells observed the 
clustering of HRS cells into two branches which displayed different signatures of the MYC, IRF4 and 
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NOTCH1 transcription factors, suggesting two distinct molecular subgroups of cHL (Tiacci et al. 
2012). The same study also showed that in clustering analysis, the HRS formed a cluster separate 
from other lymphoma types. However, when comparing different cHL subtypes to other lymphomas, 
NSCHL and LDCHL subtypes were most related to PMBCL, whereas LRCHL and MCCHL were 
closest to NLPHL. 
In several studies, the HRS cells have been reported to display various types of chromosomal 
abnormalities. Weber-Matthiesen et al. (1995) studied 30 cases of HL and found that all HRS cells 
harbored numerical hyperploid chromosomal abnormalities (Weber-Matthiesen et al. 1995). 
Frequently detected gains of chromosomal regions include, for example, regions in chromosomes 2 
and 9 spanning the candidate genes REL and JAK2 (Hartmann et al. 2008, Joos et al. 2000, Joos et al. 
2002, Steidl et al. 2010)  whereas losses have been detected in the chromosomal regions 6q and 11q 
containing the candidate genes TNFAIP3 and ATM (Chui et al. 2003, Hartmann et al. 2008, Steidl et 
al. 2010). A summary of chromosomal regions where recurrent aberrations have been detected in cHL 
is shown in Table 7.  
In addition to chromosomal aberrations, recurrent somatic mutations in cHL have been described in 
some genes of the NF-κB pathway, such as the NF-κB inhibitors TNFAIP3 (A20), IκBα (NFKBIA), 
IκBε (NFKBIE), TRAF3 and CYLD (Cabannes et al. 1999, Emmerich et al. 1999, Emmerich et al. 
2003, Jungnickel et al. 2000, Lake et al. 2009, Otto et al. 2012, Schmidt et al. 2010, Schmitz et al. 
2009a). The negative regulator of cytokine signaling, SOCS1, operating in the JAK/STAT pathway, is 
also frequently mutated in cHL (Weniger et al. 2006), whereas genes that are only rarely mutated in 










Table 7. Recurrent chromosomal aberrations in classical Hodgkin lymphoma. 
Chromosomal region Type of alteration Candidate 
gene(s) 
Reference(s) 
Chr arm 2p Gain REL (Hartmann et al. 2008, Joos et 
al. 2000, Joos et al. 2002, 
Steidl et al. 2010) 
Chr arm 6q Loss TNFAIP3 (Chui et al. 2003, Hartmann 
et al. 2008, Steidl et al. 2010)  
Chr arm 9p Gain JAK2 (Hartmann et al. 2008, Joos et 
al. 2000, Joos et al. 2002, 
Steidl et al. 2010) 
Chr arm 11q Loss ATM (Chui et al. 2003, Steidl et al. 
2010)  
Chr arm 12q Gain STAT6, CDK4, 
ERBB3, ATF1, 
DDIT3, MDM2 
(Hartmann et al. 2008, Joos et 
al. 2000, Joos et al. 2002, 
Kupper et al. 2001) 
Chr arm 13q Loss LECT1, BRCA2 (Chui et al. 2003, Hartmann 
et al. 2008, Joos et al. 2002, 
Steidl et al. 2010)  
Chr arm 16p Gain  (Chui et al. 2003, Joos et al. 
2002, Steidl et al. 2010)  
Chr arm 17p Gain  (Chui et al. 2003, Joos et al. 
2002)  
Chr arm 17q Gain MAP3K14 (Chui et al. 2003, Joos et al. 
2002, Steidl et al. 2010)  
Chr arm 19q Gain BCL3 (Hartmann et al. 2008, 
Mathas et al. 2005, Steidl et 
al. 2010) 
Chr arm 20q Gain CD40 (Joos et al. 2002, Hartmann et 
al. 2008, Steidl et al. 2010) 






(Martin-Subero et al. 2006, 
Szymanowska et al. 2008) 




(Martin-Subero et al. 2006) 
IGK locus Chromosomal 
breakpoint 
 (Martin-Subero et al. 2006) 
Chr 16p13.13 Chromosomal 
breakpoint 




5.3.2 Nodular lymphocyte predominant Hodgkin lymphoma 
The LP cells in NLPHL express many germinal center B-cell markers and they, too, were shown to 
represent a monoclonal cell population and to have identically rearranged IgV genes harboring a high 
load of somatic, although not destructive, mutations (Marafioti et al. 1997, Ohno et al. 1997). This 
suggested that LP cells originate from germinal-center B-cells. A part of the cases also showed signs 
of ongoing somatic hypermutation. 
The molecular background and pathogenesis of NLPHL is still largely unclear. A genome-wide 
expression study of LP cells suggested that NLPHL, based on its expression profile, is related to 
TCRBCL and cHL, but represents a distinct disease entity (Brune et al. 2008). The normal 
counterpart of LP cells was suggested to be germinal-center B-cell that is differentiating towards a 
memory B cell. Only a small number of genes were found to be differentially expressed in NLPHL 
compared with cHL and TCRBCL, and many of the differences between NLPHL and cHL were due 
to the more extensive B-cell marker down-regulation in HRS cells compared with LP cells. However, 
also the LP cells showed evidence of partial loss of B-cell phenotype. In addition, many apoptosis 
regulators were deregulated in the LP cells similarly to TCRBCL and other diffuse large B-cell 
lymphomas, a strong and constitutive activity of the NF-κB pathway was observed and a subset of 
NLPHL cases displayed aberrant activation of the ERK pathway (Brune et al. 2008).  
Genomic instability seems to be common in NLPHL. In a comparative genomic hybridization study 
of LP cells from 19 NLPHL cases, all cases harbored a large number of chromosomal aberrations, 
most of which were recurrent (Franke et al. 2001). This was supported by a cytogenetic study of 
NLPHL, where 12/13 of studied cases harbored complex karyotypes (Stamatoullas et al. 2007). In the 
study by Franke et al. (2001) a chromosomal rearrangement involving the BCL6 gene was also 
observed in 2/19 cases. At present, BCL6 is one of the few genes implicated in the pathogenesis of 
NLPHL, as its rearrangements have been reported to be present in a significant proportion of LP cells 
as well as in the only NLPHL derived cell line, DEV (Atayar et al. 2006, Renne et al. 2005a, 
Wlodarska et al. 2003). In the study by Renne et al. (2005a), an IGH-BCL6 translocation was found in 
five NLPHL cases. Another gene possibly involved in NLPHL pathogenesis is SOCS1, which 
harbored somatic or germline mutations in 6/12 analyzed NLPHL cases and in the DEV cell line 
(Mottok et al. 2007). SOCS1 mutations were accompanied by elevated JAK2 expression and STAT6 
activation, suggesting a role for the activation of JAK2/STAT6 pathway in NLPHL pathogenesis. 
However, activating JAK2 exon 12 mutations, which are typical for other myeloproliferative diseases, 
were not detected. Other somatically mutated genes reported in NLPHL include the aberrant somatic 
hypermutation targets PIM1, PAX5, RhoH/TTF and c-MYC (Liso et al. 2006) whereas mutations of 
TNFAIP3 (A20) and IκBα (NFKBIA) seem to be rare in NLPHL (Schumacher et al. 2010).   
5.4 Familial Hodgkin lymphoma 
It has been estimated that approximately 4.5% of HL cases are familial (Kerzin-Storrar et al. 1983). 
The relative risk of HL in the first-degree relatives of patients has been reported to be about 3-4 fold 
and a particularly high risk of HL has been observed in the monozygotic twins of HL patients (Goldin 
et al. 2004, Goldin et al. 2009, Mack et al. 1995). The first-degree relatives of children with HL also 
have an increased HL risk (standardized incidence ratio, SIR, 5.8) (Pang et al. 2008). In familial HL, 
the male to female ratio and the occurrence of different HL subtypes seem to be similar to sporadic 
HL, but the age of onset of the majority of patients is between 15 and 34 years (Ferraris et al. 1997) 
and association with EBV-infection is not observed (Lin et al. 1996). In a study based on the Swedish 
familial cancer database the heritability of HL was estimated to be ~28% (Shugart et al. 2000). The 
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same study along with a few others have also suggested anticipation in familial HL as well as in 
families with both HL and non-Hodgkin lymphoma (Alexandrescu et al. 2006, Shugart. 1998, Shugart 
et al. 2000). 
The early reports about large HL pedigrees include, for example, a consanguineous family from 
Newfoundland with several HL and common variable immunodeficiency affected individuals and an 
Amish kindred with three HL affected children (Buehler et al. 1975, Halazun et al. 1972, Marshall et 
al. 1979, Salmon et al. 1979). To date, a large number of HL families have been published, including 
four cases of familial NLPHL. Campbell et al. reported a family of two siblings of Indian origin, a 
sister and a brother, with NLPHL at the ages of 47 and 52 (Campbell et al. 2004). Bauduer et al. 
identified a French Basque family where two brothers had been diagnosed with NLPHL at the ages of 
16 and 25 and their father at the age of 67; the ages of cancer onset in the family members were 
suggested to support the hypothesis of anticipation in familial HL (Bauduer et al. 2005). Unal et al. 
reported a mother and a son from Turkey, who were both affected by NLPHL at the ages of 48 and 30 
(Unal et al. 2005), and Ur Rehman et al. described an Omani kindred of two NLPHL affected half-
brothers and a third brother with NSCHL (Ur Rehman et al. 2008). 
Many studies have aimed to clarify the genetic background in familial HL predisposition. As HLA 
region has been associated with HL in many studies, it has been an interesting candidate in studies on 
familial HL as well. Harty et al. (2002) implicated HLA-DR, HLA-DQ and TAP1 in familial HL, and 
Kamper et al. (2005) reported a family with EBV-associated pediatric HL where the patients were 
HLA I class identical (Harty et al. 2002, Kamper et al. 2005). However, in another HL family with 
three affected individuals HLA alleles did not segregate with the disease (Sonmez et al. 2010). In a 
combined linkage and segregation study of 59 HL families a two locus additive model was implicated 
and both HLA- and non-HLA associated genetic factors were suggested to contribute to familial HL 
predisposition (Shugart & Collins 2000). Other putative predisposing genetic factors in familial HL 
include a susceptibility locus on chromosomal region 4p identified in a genome-wide linkage screen 
of 44 families (Goldin et al. 2005a), genetic factors in the pseudoautosomal region (Horwitz & 
Wiernik 1999) and mutations of the KLHDC8B gene, which were recently reported in some families 
with cHL (Salipante et al. 2009). In addition, a mutation in the FAS gene has been reported in a 
patient with autoimmune lymphoproliferative syndrome and NLPHL (van den Berg et al. 2002) 
whereas Osborne et al. (2005) excluded germline NFKBIA mutations as the underlying cause of 
familial HL (Osborne et al. 2005).  
5.4.1 KLHDC8B in familial Hodgkin lymphoma 
To date, KLHDC8B gene is one of the few non-HLA candidate genes suggested in the background of 
familial cHL. Salipante et al. (2009) reported a family of three siblings with NSCHL and a mother 
with an uncharacterized mediastinal tumor who all harbored a reciprocal traslocation 
t(2,3)(q11.2;p21.31) (Salipante et al. 2009). The translocation was found to displace the 5’UTR and 
putative promoter of the KLHDC8B gene resulting in reduced expression of the KLHDC8B protein. 
In addition, a polymorfism in the 5’UTR of the gene was found to segregate with cHL in 3/52 studied 
cHL families and to result in decreased expression.  
KLHDC8B is a protein of the Kelch-family, and it was proposed to consist of seven kelch repeat 
domains (Krem et al. 2010). Functional characterization of KLHDC8B revealed that the protein is 
expressed solely in mitotic cells, it locates to the midbody of dividing cells and that it is mostly 
present during cytokinesis and degraded afterwards (Krem et al. 2010, Salipante et al. 2009). These 
factors suggested that KLHDC8B is important in cytokinesis. In addition, RNA interference 
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knockdown of KLHDC8B in HeLA cells increased the occurrence of binucleated cells, which are 
typical in cHL (Salipante et al. 2009). Based on a small interfering RNA experiment targeting the 
untranslated regions of KLHDC8B, Salipante et al. (2009) also proposed that the 5’UTR of 
KLHDC8B is essential for the protein to function correctly in cytokinesis. Further studies on various 
cell types subsequently showed that the disrupted function of the KLHDC8B protein causes 
multinucleated cells, impaired cytokinesis and aneuploidy and that KLHDC8B plays a role in 
maintaining mitotic integrity and chromosomal stability (Krem et al. 2012). These factors suggested 
that impaired KLHDC8B function might in part account for some of the distinct characteristics of 
HRS cells, particularly the multinuclear phenotype as well as chromosomal instability. 
 
6. Primary mediastinal large B-cell lymphoma 
PMBCL was in 2001 distinguished as a distinct lymphoma entity in the WHO classification (Jaffe et 
al. 2001 p.175). It is considered as a DLBCL with distinctive clinicopathological features, and it 
accounts for 2-4% of NHLs and for 6-10% of DLBCLs (Martelli et al. 2008, Swerdlow et al. 2008 
p.250). In PMBCL, the primary tumor site is the mediastinum. Most patients are females, and the 
median age of onset in PMBCL is 30-35 years. The malignant cells in PMBCL have been suggested 
to originate from putative thymic B-cells and the risk factors of PMBCL are unknown. The diagnosis 
of PMBCL is based on specific clinical information, morphology and immunophenotypic as well as 
genetic data (Martelli et al. 2008, Swerdlow et al. 2008 p.250). 
6.1 Clinical and histopathological features 
The majority of patients with PMBCL present with symptoms at an early stage of the disease, and the 
symptoms are often related to the large anterior mediastinal tumor mass (Martelli et al. 2008). In 
many cases, the tumor diameter exceeds 10 cm and it may directly infiltrate adjacent tissues and 
structures, for example pleura, pericardium and lung. Common symptoms include vena cava 
syndrome, compression of the airways, cough and dyspnea and most patients (~80%) have a stage I-
II disease at the time of diagnosis. PMBCL may also spread to cervical and supraclavicular lymph 
nodes (Swerdlow et al. 2008 p.250). In a disseminated disease, involvement of extranodal sites such 
as kidney, liver and brain is quite common, whereas bone marrow is usually not affected. In fact, to 
enable the differential diagnosis between PMBCL and systemic DLBCL with mediastinal 
involvement, it has been recommended in the World Heath Organiztion classification that PMBCL 
diagnosis should be considered only in the absence of bone marrow and peripheral, except 
supraclavicular and cervical, lymph node involvement (Swerdlow et al. 2008 p.250). 
The clinical staging of PMBCL is based on the Ann Arbor/Cotswolds classification originally 
proposed for HL (Table 6) (Martelli et al. 2008). In addition, the patients are classified according to 
whether they have systemic symptoms (fever, night sweats and weight loss) and/or a bulky disease 
(tumor width > 1/3 thorax diameter). The optimal chemotherapy in PMBCL is still to be established, 
and two different chemotherapy options are commonly used, CHOP (cyclophosphamide, doxorubicin, 
vincristine and prednisone) and MACOP-B (methotrexate, doxorubicin, cyclophosphamide, 
vincristine, prednisone and bleomycin) (Zinzani & Piccaluga 2011). However, studies have reported 
better overall survival rates with the latter and in addition, a role for rituximab in combination with 
CHOP is emerging (Vassilakopoulos et al. 2012, Zinzani & Piccaluga 2011). Mediastinal 
radiotherapy is often used to follow chemotherapy, and in many studies it has been reported to 
increase the proportion of patients achieving complete remission or to correlate with better overall 
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survival (Zinzani & Piccaluga 2011). However, radiotherapy increases the risk of secondary breast 
and lung cancer. In PMBCL, many studies have reported 5-year overall survival rates of 50-65% 
(Reviewed in Zinzani & Piccaluga 2011). Recently, a 5-year overall survival of 97% was reported 
from a phase 2 study where 51 patients with PMBCL were treated with dose-adjusted EPOCH-R 
(etoposide, doxorubicin, cyclophosphamide, vincristine, prednisone, rituximab) but without 
radiotherapy (Dunleavy et al. 2013). Thus, in the future, EPOCH-R may emerge as a new treatment 
option for PMBCL. As the treatment of relapses is often unsuccessful in PMBCL, and effective first-
line therapy is considered particularly important (Steidl & Gascoyne 2011). 
In PMBCL, the histopathological and morphological features vary between individual cases and may 
resemble both DLBCL and NSCHL (Swerdlow et al. 2008 p.250). The malignant cells are medium-
sized or large and the cytoplasm is pale and abundant. In most cases the nuclei are round, but 
occasionally they can be multilobated as in HRS cells, and the tumor cells are compartmentalized by 
fibrotic bands. The tumor cells express many B-cell markers such as CD19, CD20, CD22 and CD79a. 
CD30 is also expressed in most cases, but the staining is weaker and more heterogeneous than in 
cHL. PMBCL frequently stains positively for IRF4/MUM1, BOB1, PU.1, OCT2, PAX5, BCL6, 
CD23 and BCL2 (Steidl & Gascoyne 2011, Swerdlow et al. 2008 p.250). Surface immunoglobulin is 
not expressed, expression of HLA I and II molecules is often defective, expression of CD10 and 
CD15 are uncommon and EBV is absent.  
6.2 Molecular background 
PMBCL has been suggested to arise from thymic germinal center or postgerminal center B-cells as in 
most cases the tumor cells harbor somatic BCL6 and IgVH mutations indicating that the cells have 
undergone somatic hypermutation (Csernus et al. 2004, Pileri et al. 2003). The immunoglobulin 
genes are clonally rearranged and isotype-switched and ongoing mutation is not detected (Leithauser 
et al. 2001).  
Expression studies comparing PMBCL with other DLBCLs and cHL have revealed common features 
between PMBCL and cHL (Rosenwald et al. 2003, Savage et al. 2003). Constitutive activity of the 
NF-κB pathway, leading to increased expression of cell survival promoting and antiapoptotic targets, 
has been observed in PMBCL, suggesting an important role for this pathway in the pathogenesis the 
disease (Feuerhake et al. 2005). Another activated pathway is the JAK/STAT pathway, and high 
expression of IL-13 receptor, JAK2 and STAT1 as well as constitutive activation of STAT6 have 
been reported in PMBCL (Guiter et al. 2004, Savage et al. 2003). In addition, defective HLA class II 
molecule expression has been suggested to play a role in PMBCL, possibly by enabling immune 
escape of the malignant cells (Steidl & Gascoyne 2011). 
In genomic analyses, the most frequently observed gains and/or amplifications involve the 
chromosomal regions 2p16, containing the candidate gene REL, and 9p24, encompassing the 
candidate genes JAK2, the immunoregulators PDL1 and PDL2, and the histone demethylase JMJD2C 
(Bea et al. 2005, Green et al. 2010, Rui et al. 2010, Weniger et al. 2007, Wessendorf et al. 2007). 
Chromosomal losses in PMBCL are less well studied; however, losses of the regions 1p, 3p, 4q, 6q, 
7p and 17p been reported in a few studies (Kimm et al. 2007, Wessendorf et al. 2007). Of these, the 
6q region involves the candidate gene TNFAIP3 (Steidl & Gascoyne 2011). A recurrent chromosomal 
rearrangement reported in PMBCL (as in cHL) is the gene fusion of CIITA (MHC class II 
transactivator) with various partners which, interestingly, results to downregulation of the molecules 
of HLA class II and increased PDL1 and PDL2 expression (Steidl et al. 2011). In PMBCL, recurrent 
somatic sequence mutations or other alterations have been reported in TNFAIP3, STAT6, SOCS1, 
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p16/Ink4, C-MYC and TP53 (Melzner et al. 2005, Ritz et al. 2009, Scarpa et al. 1999, Schmitz et al. 




Aims of the study 
 
The aim of this thesis was to study the genetic background of familial lymphoma predisposition. The 
specific aims were: 
 
1. To analyze whether germline mutations in KLHDC8B underlie genetic predisposition to nodular 
lymphocyte predominant Hodgkin lymphoma 
 
2. To identify a candidate susceptibility gene for familial nodular lymphocyte predominant Hodgkin 
lymphoma 
 
3. To evaluate the risk of nodular lymphocyte predominant Hodgkin lymphoma in the first-degree 
relatives of patients 
 
4. To clinically characterize a family with primary mediastinal large B-cell lymphoma 




















Materials and methods 
 
1. Subjects and samples  
1.1 Lymphoma families (I, II, IV) 
In studies I and II, genomic DNA (gDNA) extracted from blood samples was obtained from a Finnish 
family of four cousins affected by NLPHL, “Family 1” (Figure 4), and from three previously 
published NLPHL families from the United Kingdom (UK)/India, France and Turkey (Bauduer et al. 
2005, Campbell et al. 2004, Unal et al. 2005). In addition, formalin fixed paraffin embedded (FFPE) 
tumor tissue was collected from all four NLPHL cases in Family 1 (III-1, III-2, III-13 and III-14, 
Figure 4). 
In study I, gDNA was available from the four NLPHL cases in Family 1 (Figure 4) and from two 
NLPHL cases from each of the other families. The collected tumor samples were reviewed to confirm 
diagnoses. The clinical details have been described in the original publication (study I). 
In study II, gDNA from eleven members of Family 1 (II-1-4, II-6, III-1, III-2, III-7, and III-13-15, 
Figure 4) was used for obtaining genome-wide genotype data and for direct sequencing. Lymphoblast 
cell lines were also available from the same individuals. Blood-extracted RNA was available from ten 
family members. Karyotype analysis and exome sequencing were performed from III-1. The tumor 
samples of the NLPHL cases in Family 1 were evaluated for the presence of EBV. In study II, the 
NPAT gene was analyzed in the three previously reported NLPHL families, and lymphoblast cell lines 
were available from four members of the French family and from one patient with NLPHL in the 
UK/India family. 
 
Figure 4. The Finnish lymphoma families. In Family 1, four cousins have been diagnosed with 
nodular lymphocyte predominant Hodgkin lymphoma. In Family 2, three siblings are affected by 
primary mediastinal large B-cell lymphoma and their cousin by extranodal diffuse large B-cell 
lymphoma. The number of children is shown as numbers inside diamonds. The pedigrees have been 
modified for confidentiality.  
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In study IV, a Finnish family of four DLBCL cases was characterized. In this “Family 2” (Figure 4), 
two sisters (cases 1 and 3) and their brother (case 2) had been diagnosed with DLBCL and they all 
had a primary tumor in the mediastinum. In addition, their maternal cousin (case 4) had been 
diagnosed with extranodal DLBCL with a tumor between the uterus and the urinary bladder. The 
medical records of all four patients were scrutinized and their tumor samples were collected and 
examined to determine detailed diagnoses. Genomic DNA extracted from blood was obtained from 
cases 1, 3 and 4, from the healthy mother and one healthy sibling of cases 1-3, and from two healthy 
children of case 2, and gDNA extracted from FFPE tumor tissue was obtained from cases 1-4. The 
karyotype of case 3 had been previously studied and found normal. 
1.2 Validation material (II, IV) 
In study II, validation material from additional HL cases was used for mutation screening of NPAT. 
FFPE tissue derived gDNA was available from 73 Finnish patients. Twenty-seven were familial 
lymphoma cases with at least one case of NLPHL in the family, 38 were early-onset NLPHL cases 
and 8 were NLPHL cases who were born in the same geographical region as the patients in Family 1 
(Figure 4). The 73 HL patients were identified by using a systematic search for patients with NLPHL 
from the Finnish Cancer Registry (FCR). NPAT was also analyzed from the blood derived gDNA of 
93 HL cases from the UK, including 26 patients with a relative affected by a lymphoproliferative 
disorder, and from the NLPHL-derived cell line DEV (Atayar et al. 2006) provided by Dr. Sibrand 
Poppema. 
In study IV, the MLL amino acids 1820-1868 were screened by direct sequencing from a validation 
set of 106 NHL cases. The validation set included FFPE tissue derived gDNA from 14 familial and 9 
early-onset NHL cases who were identified in a search for related NHL cases from the FCR. In 
addition, gDNA derived from fresh frozen tumor tissue, lymph node biopsy material, bone marrow 
aspirate or blood was available from 83 sporadic DLBCL cases from Finland, of which 42 were 
anonymous patients.   
1.3 Patients with NLPHL diagnosis in the FCR (III) 
The FCR, founded in 1952, is a nationwide institution which registers all cancers in Finland. In the 
FCR database, all subtypes of HL were until 2006 classified into the same category, “HL”. To identify 
patients with NLPHL diagnosis, NLPHL-related keyword searches were performed from the free text 
contents of the FCR database. The keyword searches focused to patients with HL who had been 
diagnosed before the end of December 2009. The clinical and pathologic Cancer Registry reports of 
all patients (n=744) who matched the keywords were extracted, manually examined and interpreted to 
exclude patients without a diagnosis of NLPHL. In total, 693 individuals with NLPHL diagnosis were 
identified, and they were reclassified as separate group (NLPHL) in the FCR database to enable the 
calculation of SIR in the family member cohort. 
1.4 Collection of the cohort of first-degree relatives of NLPHL patients (III) 
Genealogy work was done by utilizing the Population Registry Center and Church Parish Registers. 
The first-degree relatives of 692 NLPHL cases were successfully identified. Data was collected from 
altogether 4280 first-degree relatives who had a personal identity code (PIC), and these 4280 relatives 
comprised the family member cohort that was used in the statistical analyses. The Population Registry 
Center was used to acquire the PICs as well as the dates of emigration and death. Cancer data for all 
the first-degree relatives was obtained from the FCR, and the detailed Cancer Registry reports of all 
relatives affected by any type of HL were collected and manually examined. 
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1.5 Healthy controls (II, IV) 
Blood-extracted gDNA was available from 282 and 86 anonymous healthy Finnish blood donors in 
studies II and IV, respectively. In addition, 177 healthy individuals from the UK, participating in the 
National Study of Colorectal Cancer Genetics, were used as controls in study II (Penegar et al. 2007). 
The controls were geographically matched with patients. 
2. Histopathologic examination of tumor samples  
In study I, the tumor samples of four NLPHL cases in Family 1 (III-1, III-2, III-13 and III-14, Figure 
4) were available for histopathological revision. In study III, FFPE primary tumor samples were 
collected from 20 first-degree relatives affected by HL. Of these, 10 were from relatives with a 
NLPHL diagnosis in the FCR, 9 were from relatives with the diagnosis of some other type of HL and 
one was from a relative with both NLPHL and MCCHL diagnoses in the FCR, but he had not been 
identified as a NLPHL case in the keyword search due to misspelling of the NLPHL diagnosis. In 
addition, tumor tissue derived from a relapse (10 years later) was obtained from one relative with 
NLPHL diagnosis. In both studies, sections from the tumor samples were stained with HE, CD20, 
CD30, CD15 and CD3.  
In study II, EBV-encoded RNA in situ hybridization was performed from the tumor samples of III-1, 
III-2, III-13 and III-14 (Figure 4) at HUSLAB (Ts-PAD-ISH, 4192).  
In study IV, tumor samples were obtained from cases 1-4 in Family 2 (Figure 4) and stained with HE, 
CD20, CD30, CD10, CD23, MIB1, IRF4/MUM1, BCL2, BCL6, PAX5, OCT2, BOB1 and LMP-1.  
HE staining was performed according to a standard protocol, and immunohistochemical stainings 
were performed at HUSLAB. In all four studies, the stained sections were reviewed by 
hematopathologist (I, III, IV) or other pathologist (II).  
3. Genetic studies  
3.1 Extraction of DNA and RNA (I, II, IV) 
Extraction of gDNA from peripheral blood was performed by following a non-enzymatic protocol 
modified from (Lahiri & Nurnberger 1991). Genomic DNA from FFPE tissue was extracted using 
standard procedures. RNA was extracted from cell lines and peripheral blood by utilizing RNeasy kit 
(Qiagen Inc., Valencia, CA, USA) and PAXgene Blood RNA kit (Qiagen), respectively.  
3.2 SNP array and linkage analysis (II, IV) 
Genome-wide SNP genotyping was performed with Affymetrix 50K Xba SNP array (Affymetrix Inc., 
Santa Clara, CA, USA) (study II) or with HumanOmniExpress-FFPE BeadChip (Illumina Inc, San 
Diego, CA, USA) (study IV) at the Institute for Molecular Medicine Finland (FIMM) Genome and 
Technology Center. The manufacturer’s instructions were followed in all procedures. In Family 1, 
individuals II-1-4, II-6, III-1, III-2, III-7 and III-13-15 (Figure 4) were genotyped (study II) and in 
Family 2 cases 1-4, the healthy mother of cases 1-3, and two healthy children of case 2 (Figure 4) 
were genotyped  (study IV). Blood derived gDNA was used for genotyping of all other individuals 





The SNP array data was analyzed using Merlin (Abecasis et al. 2002). In study II, parametric 
recessive and dominant models were analyzed, whereas in study IV only parametric dominant model 
was analyzed. In study II, linkage was also confirmed by using microsatellite markers, which were 
either derived from the Ensembl database (www.ensembl.org) or identified by using Tandem repeats 
finder (Benson 1999). A list of the used microsatellite markers is shown in the supplemental data of 
study II. Microsatellite PCRs were performed according to a standard protocol and capillary 
electrophoresis was run on ABI3730 (Applied Biosystems, Foster City, CA, USA). The results were 
visualized and scored with GeneMarker (Softgenetics, State College, PA, USA). Haplotyping of the 
microsatellite marker alleles was done manually. 
3.3 Exome sequencing and data analysis (II, IV) 
Altogether, the exomes of three individuals were sequenced from blood-extracted gDNA (Table 8). 
Sample preparation was done with NEBNext® DNA Sample Prep Reagent Set 1 Kit (New England 
Biolabs Ltd., Hitchin, United Kingdom). Enrichment of exomic regions was performed with Agilent 
Sure Select All Exon Kit v.1 (Agilent, Santa Clara, CA, USA), and short-read sequencing was 
performed with Illumina Genome Analyzer II (Illumina) at the FIMM Genome and Technology 
Center Finland. The details of exome sequencing and data analysis in studies II and IV are shown in 
Table 8 and Table 9. 
After exome data analysis and filtering of identified variants (exclusion of silent variants and variants 
found in control exomes and databases) the exome data was integrated with linkage data. All putative 
variants residing in linked regions were selected for validation by direct sequencing.  
Table 8. The details of exome sequencing and data analysis in studies II and IV. 
 Study II Study IV 
Analyzed individuals III-1 (Family1, Figure 4) Cases 1 and 3 in                  
(Family 2, Figure 4) 
Read length (base pairs) 56 58 and 82  
Analysis software NextGene 1.94 (Softgenetics) In-house analysis pipeline* and 
RikuRator (unpublished) 
Reference genome  NCBI36/Hg18 GRCh37/Hg19 
Analyzed region Exons and exon-intron boundaries 
(2bp) 
Exons and exon-intron boundaries 
(2bp) 
Minimum coverage required 5 reads 2 reads 
Minimum coverage for a mutated 
allele 
20% of reads, at least two reads 20% of reads 
Control exomes 13 196 
Excluded variants Synonymous variants and database 
polymorfisms 
Variants not found in both exomes; 
Synonymous variants and database 
polymorfisms 
*see Table 9; bp, basepairs 
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Table 9. In-house analysis pipeline for raw exome sequencing data (study IV). 
Action Analysis method Reference 
Quality check of the 
raw data 
FastQC program http://www.bioinformatics.bbsrc.ac.uk/projects/fastqc/ 
Removal of 3’ ends 
with adapter 
similarity 
In-house script  
Read alignment to 
reference genome 
BWA (Li & Durbin 2009) 










(McKenna et al. 2010) 





(McKenna et al. 2010) 
 
3.4 Direct sequencing (I, II, IV) 
PCR primers were designed with Primer3 (www.frodo.wi.mit.edu/primer3) and/or ExonPrimer 
(www.ihg.gsf.de/ihg/ExonPrimer.html) separately for FFPE tissue and blood derived gDNA and 
cDNA. NCBI36/Hg18 or GRCh37/Hg19 was used as reference sequence, and they were accessed via 
the Ensembl database (www.ensembl.org) and the University of California Santa Cruz (UCSC) 
Genome Browser (http://genome.ucsc.edu/). PCR was performed by following standard protocols. 
Purification of PCR products was done using ExoSAP-IT (USB Corporation, Cleveland, OH, USA). 
BigDye v.3.1. sequencing reaction and electrophoresis on ABI3730xl DNA Analyzer (Applied 
Biosystems) were performed at the FIMM Genome and Technology Center. Sequences were analyzed 
with Chromas (www.technelysium.com.au) and Mutation Surveyor (Softgenetics, State College, PA, 
USA).  
3.4.1 Mutation analysis and verification of exome variants  
In study I, the KLHDC8B gene (ENST00000332780), including all six exons, exon-intron boundaries 
and the 5’UTR, was analyzed by direct sequencing in Family 1 as well as in the three previously 
reported NLPHL families. The primer sequences are shown in the supplemental table (Table S1) of 
study I.  
In studies II and IV, candidate variants (exome variants residing in linked/segregating genomic 
regions) were sequenced to verify the variants. The segregation of validated variants was analyzed in 
additional family members, and segregating variants were screened from healthy controls. Emerged 
candidate variations were screened in healthy family members. In study II, the NPAT (CCDS41710) 
gene was sequenced from the available validation material (section 1.2.) and from the three foreign 
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NLPHL families. In study IV, the validation material (section 1.2.) was used to screen the putative 
MLL (NM_001197104.1) domain region spanning amino acids 1820-1868.  
3.4.2 Analysis of NPAT cDNA  
In study II, RNA was extracted from the established lymphoblast cell lines (section 1.1.) and the 
NLPHL-derived cell line DEV (Atayar et al. 2006). Reverse transcription to cDNA was performed 
using random primers and M-MLV enzyme (Promega, Madison, WI, USA). NPAT cDNA was 
sequenced as described above. 
3.4.3 Analysis of MLL loss of heterozygosity 
In study IV, gDNA derived from FFPE tumor tissue of cases 1-4 was studied by direct sequencing for 
possible loss of heterozygosity at the site of the MLL c.5533C>A variation. 
3.5 Gene expression analysis (II) 
GeneChip Human Genome U133 Plus2 (Affymetrix) was used to obtain transcriptome-wide gene 
expression data from blood derived RNAs of II-1-3, II-6, III-1, III-2, III-7, III-13-15 (Figure 4) and 10 
controls. The data was normalized (robust multichip average normalization) in R (www.r-project.org) 
by utilizing custom chip definition files (ENTREZG, v. 11.1.1.) (Dai et al. 2005). The expression of 
NPAT was analyzed using two-tailed t-test with equal variance assumption; 8 mutation carriers were 
compared with 12 non-carriers.  
4. Statistical analysis  
4.1 Odds ratio (II) 
To evaluate the association of the NPAT serine 725 deletion with HL, odds ratios and 95% confidence 
interval (CI) were calculated by using unconditional logistic regression. The calculation was 
performed with STATA v. 10.0 (Stata Corporation, College Station, TX, USA). Only successfully 
sequenced HL patients with geographically matched controls available were included in the analysis. 
4.2 Standardized incidence ratio (III) 
The SIRs for different cancers, including all cancers, NHL, HL and NLPHL, were calculated in the 
cohort of 4280 identified first-degree relatives on the basis of the diagnoses available in the FCR 
(registry-based SIRs). In addition, the SIR for NLPHL was calculated on the basis of the number of 
relatives with a histopathologically verified NLPHL diagnosis. The SIRs were calculated for all first-
degree relatives, relatives of early onset patients (< 30 years old at diagnosis) and relatives of late 
onset patients (> 30 years old at diagnosis) as well as for different sexes.  
The follow-up period for cancer incidence in the cohort started in January 1971 and ended in 
December 2009. For parents, the follow-up started on the birthday of the NLPHL proband. For 
siblings and children, the follow-up started when they were born. The follow-up ended to emigration 
or death.  
The SIRs were calculated as a ratio of observed cancers and expected number of cancers. Both 
numbers were derived from the FCR for the calculation of registry-based SIRs. The number of 
expected cases was evaluated from the average incidence in the Finnish population for each sex, age 
group and calendar period. For the calculation of SIR on the basis of confirmed NLPHL diagnoses, 
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only those first-degree relatives whose NLPHL diagnosis was histopathologically verified were 
considered as observed cases. Calculation of the 95% CIs was based on the assumption that the 
number of observed cases was distributed according to the Poisson distribution. In addition, the 
cumulative cancer incidence rates for all lymphomas, all HL subtypes and NLPHL were calculated in 
the first-degree relatives by using the 5-year age category incidence rates.  
5. In silico prediction  
In study IV, the effects of MLL 5533C>A and SORL1 1870C>T variants on protein function were 
predicted with PolyPhen2 (http://genetics.bwh.harvard.edu/pph2/) (Adzhubei et al. 2010). The 
HumDiv-model was used.  
6. Ethical issues  
All studies have been approved by the Ministry of Social Affairs and Health.  
Studies I, II and IV have been approved by the ethics committees of the Department of Medical 
Genetics of the University of Helsinki and/or the Hospital District of Helsinki and Uusimaa. Patient 
samples were obtained either after informed consent or authorization from Valvira (National 
Supervisory Authority for Welfare and Health).  
Samples from anonymous DLBCL patients in study IV were obtained with the permission from the 


















1. Identification of a new NLPHL family and mutation screening of 
KLHDC8B (I) 
In this study, a new Finnish family with four cousins diagnosed with NLPHL was reported (Family 1, 
Figure 4). The family was originally identified when one of the patients with NLPHL was referred to 
genetic counseling. Three of the patients were males and one was female. The youngest patient with 
NLPHL in this family was 22 at the time of cancer onset, and the oldest was 26. The NLPHL 
diagnosis was confirmed for all four patients in the histopathological re-evaluation of the tumor 
samples. In all cases, the malignant cells were CD20 positive, and negative for CD30, CD15 
(although one case was CD15+/-), and CD3. The occurrence of four patients with the rare HL subtype 
in the same family raised a suspicion of an inherited predisposition to NLPHL.  
Germline mutations of the KLHDC8B gene have been implicated in familial cHL in four families 
(Salipante et al. 2009). Thus, we analyzed the KLHDC8B gene in the new Finnish NLPHL family and 
in three previously reported families (Bauduer et al. 2005, Campbell et al. 2004, Unal et al. 2005) to 
clarify whether variations of the same gene also underlie genetic predisposition to NLPHL. 
KLHDC8B is a gene spanning 354 amino acids. The 5’UTR, exons, and exon-intron boundaries were 
screened by direct sequencing. One database variation in the gene was detected: rs9586 (C>T) with a 
minor allele frequency of 0.19 (www.ensembl.org). Previously unreported variations segregating with 
NLPHL were not found in any of the four families, suggesting that variations of the KLHDC8B gene 
are not the predisposing factor in familial NLPHL. 
2. NPAT in Hodgkin lymphoma (II) 
As screening of the KLHDC8B gene failed to identify the genetic factor underlying familial NLPHL, 
Family 1 (Figure 4) was further studied by using a genome-wide approach. To identify a candidate 
gene for familial NLPHL, two relatively new systematic methods, genome-wide SNP-array based 
linkage analysis and exome sequencing, were utilized.  
2.1 Karyotype analysis and EBV-encoded RNA in situ hybridization 
The karyotype of III-1 (Family 1, Figure 4) was studied. The resolution of the analysis was 400-500 
bands, and the result was normal, thus excluding major chromosomal rearrangements as the cause of 
NLPHL susceptibility in Family 1. The tumors of III-1, III-2, III-13 and III-14 (Figure 4) were EBV-
negative, as is typical in NLPHL. 
2.2 Linkage analysis and exome sequencing 
By using a parametric dominant model, linkage analysis revealed 13 genomic regions segregating 
with NLPHL in Family 1. The linked regions are shown in Table 2 of the original publication (study 
II). Altogether, the regions spanned over 112 Megabases (Mb). Finemapping with microsatellite 
markers did not exclude any of the regions. Exome sequencing of III-1 (Figure 4) yielded over 7000 
putative variants, which were further filtered against databases and 13 control exomes available from 
other projects. After filtering, linkage data and exome data were integrated and further analyses were 




2.3 Candidate variants 
Fourteen candidate variants were found in the linked regions. Analysis by direct sequencing verified 
seven of the variants (Table 10).  
Table 10. The exome variants that were verified by direct sequencing. 
Gene Nucleotide change Amino acid change In healthy controls 
KRT85 12:51045077 189D>DN 1/3 
MIP 12:55134346 107V>VI 2/3 
NPAT 11:107548485- 107548486 c.2437-2438delAG 0/239 
POF1B X: 84456108 315R>C 2/251 
SLC22A14 3:38324153- 38324156 c.713-716delTGTT 1/3 
DDIT3 12:56196899 157R>RQ no segregation 
DGKA 12: 54620452 296T>TA 2/110 
 
Six of the validated variants segregated in the affected family members in Family 1. However, three 
variants were detected in a preliminary set of three controls, and two other variants were detected in 
healthy controls when a larger amount of controls was studied (Table 10). Thus, only one segregating 
variant was not found in healthy controls (n=239): a heterozygous c.2437-2438delAG in the exon 13 
of the NPAT gene (Figure 5). This deletion of two basepairs leads to a premature stop codon in exon 
13 of NPAT. In addition to the patients with NLPHL in Family 1, the deletion was found in II-1, II-3-
4, II-6 and III-15.   
 
 






2.4 NPAT mutation screening 
The 18 exons and the exon-intron boundaries of NPAT were analyzed in the available validation 
material (Materials and Methods, 1.2.) and in the three previously published NLPHL families 
(Bauduer et al. 2005, Campbell et al. 2004, Unal et al. 2005). Another variation, a deletion of the 
serine residue 725 (Ser725) was found in seven HL patients in the validation material (Table 11). The 
site of the Ser725 deletion was screened also from the available healthy controls, and deletion of 
Ser725 was detected in 5 individuals. Of note, the number of the serine residue is 725 in the main 
transcript of NPAT. In the original publication, the serine residue was numbered according to a 
different transcript (and was thus named as Ser724).   
Table 11. Characteristics of the patients with HL with Ser725 deletion. 
 
Case Nationality Sex Diagnosis Age of onset Family history 
I Finnish Male NLPHL 21 no 
II UK Female Unspecified HL 23 no 
III UK Female Unspecified HL 23 no 
IV UK Female Unspecified HL 30 no 
V UK Female Unspecified HL 14 no 
VI UK Female Unspecified HL 50 Yes, first-degree 
relative with NHL 
VII UK Female Unspecified HL 64 Yes, first-degree 
relative with HL 
 
In addition, the NPAT cDNA was analyzed in Family 1, the UK/India and French families, and in the 
NLPHL-derived cell line DEV. Additional mutations were not detected. In the cDNA sequences of 
the mutation carriers in Family 1, the mutated NPAT allele showed a lower intensity, with the peaks 
reaching about 1/3 of the wild-type allele.  
2.5 Odds ratio 
The odds ratio for the association of Ser725 deletion with HL was calculated on the basis of the 
observed frequency of the deletion in the Finnish and UK patients and healthy controls. At the site of 
the Ser725 deletion, 93% of the HL patients and 97% of the available controls were successfully 
screened by direct sequencing, and thus, the odds ratio was 4.11 (95% CI, 1.27-13.35, p=0.018) 







2.6 NPAT expression 
NPAT expression in blood in the c.2437-2438delAG mutation carriers was studied by comparing 
eight mutation carriers with twelwe non-mutation carriers. The mRNA level of NPAT was reduced in 
the mutation carriers, with a fold change of 0.80. The result was statistically significant (p=0.016). 
Decreased expression of NPAT may imply that the product of the mutated allele is directed to 
nonsense mediated decay. 
3. Familial risk in NLPHL (III) 
NLPHL is a rare subtype of HL, and its risk factors are mostly unclear. To evaluate the risk of 
NLPHL and other lymphomas in the first-degree relatives of patients, patients with NLPHL diagnosis 
were first searched from the FCR. Then, relatives of patients were systematically identified by using 
genealogy work and the Finnish registers. The identified relatives comprised the family member 
cohort which was used to calculate the SIRs for NLPHL, cHL (including HL NOS), NHL and all 
cancers. 
3.1 Patients with NLPHL diagnosis in the FCR 
By utilizing keyword-searches, a total of 693 patients with NLPHL diagnosis were found from the 
FCR database. Statistics on these patients are shown in Table 12. The relatives of all except one 
patient were identified.  
Table 12. Patients with NLPHL diagnosis identified from the FCR. 
Men 518 (75%) 
Women 175 (25%) 
Mean age at diagnosis 30-50 years 
NLPHL/HL ratio in 1980-2008 16.6% 
NLPHL/HL ratio before 1980 0-6.9% 
Patients with FCR notifications that include other HL 
subtypes in addition to NLPHL 









3.2 The first-degree relatives 
The first-degree relatives of 692 patients with NLPHL diagnosis in the FCR were identified. In total, 
the family member cohort consisted of 4280 first-degree relatives. However, 154 relatives had died or 
emigrated before the beginning of the follow-up period or were born after the end of the follow-up. 
Thus, they were not included in the statistical analysis. The 4126 relatives included in the statistical 
analysis are described in Table 13. The cancer data collected from the FCR revealed that in the final 
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family member cohort of 4126 relatives, there were altogether 607 observed cancers, 35 NHLs, 15 
cHLs (including HL NOS) and 12 NLPHLs (Table 13).  
Table 13. The number of identified first-degree relatives in each subgroup that was analyzed. The 
number of cancers in each subgroup is also shown.  
Relatives Number of 
relatives 
All cancers NHLs cHLs NLPHLs 
All relatives 
  Males 


















  Males 
  Females 






















  Males 
  Females 




















cHL includes also Hodgkin lymphoma, not otherwise specified 
3.3 Registry-based SIRs 
The registry-based SIRs were calculated on the basis of the cancer data obtained from the FCR. The 
results that were statistically significant (p < 0.05) are listed; full results are shown in Table 3 of the 
original publication (study III). The relative risk of all cancers was slightly elevated in all relatives 
(SIR 1.1, 95% CI 1.1-1.2), male relatives of all patients (SIR 1.2, 95% CI 1.1-1.3), relatives of late-
onset patients (SIR 1.2, 95% CI 1.1-1.2) and male relatives of late-onset patients (SIR 1.2, 95% CI 
1.0-1.3). The risk of NHL was somewhat increased in the same groups: the SIR was 1.9 in all 
relatives (95% CI 1.3-2.6), 2.2 in male relatives (95% CI 1.4-3.4), 1.9 in relatives of late-onset 
patients (95% CI 1.3-2.7) and 2.2 in male relatives of late-onset patients (95% CI 1.3-3.5). 
The relative risk of cHL was clearly elevated in the registry-based analysis. In all relatives, the SIR 
for cHL was 5.3 (95% CI 3.0-8.8); in male relatives the SIR was 6.0 (95% CI 3.6-15) and in female 
relatives 4.7 (95% CI 1.7-10). In the relatives of early-onset patients, the SIRs for cHL were not 
statistically significant. In the relatives of late-onset patients, the SIR for cHL was 6.0 (95% CI 3.3-
10); in male relatives of late-onset patients it was 7.1 (95% CI 3.2-13) and in female relatives 4.7 
(95% CI 1.5-11).  
The registry-based SIR for NLPHL in all relatives was 26 (95% CI 13-45). In male relatives, the SIR 
for NLPHL was 17 (95% CI 6.4-38) and in female relatives it was 48 (95% CI 18-110). The SIR for 
NLPHL in the relatives of early-onset patients was 60 (95% CI 19-140); in male relatives of early-
onset patients the SIR was 30 (95% CI 3.7-110) and in female relatives the SIR was 170 (95% CI 34-
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490). In the relatives of late-onset patients, the SIR was 18 (95% CI 7.3-37); in male relatives of late-
onset patients the SIR was 14 (95% CI 3.9-37) and in female relatives the SIR was 28 (95% CI 5.9-
83). The cumulative incidences of all lymphomas, all HL subtypes and NLPHL were 3.4%, 1.3% and 
0.6%, respectively. 
3.4 Results of the histopathologic re-examination 
The primary tumor samples of 10/12 first-degree relatives with NLPHL diagnosis in the FCR were re-
examined. One of these relatives had the diagnoses of both NLPHL and LRCHL. The NLPHL 
diagnosis was validated for seven relatives, whereas in three cases the diagnosis was changed to cHL 
(Table 14). The relapse tumor of one relative was diagnosed as TCRBCL. In addition, the primary 
tumor samples of 10/15 relatives with some other HL diagnosis in the FCR were re-reviewed. Two 
cases, including one with HL, not otherwise specified, and one with the diagnoses of MCCHL and 
NLPHL with a spelling error, were verified to have NLPHL. For two other cases, the original 
diagnosis of HL was changed to NHL and malignant tumor not otherwise specified. Table 14 
describes those relatives whose diagnosis was changed in the histopathological examination. 
Table 14. The first-degree relatives, whose original diagnosis was changed after the histopathological 
re-evaluation of primary tumor samples. 
Sex Year of 
diagnosis 
Original diagnosis            
(in the FCR) 
Immunophenotype Verified diagnosis 
M 2005 NLPHL and LRCHL CD20+, CD30+/-, CD15+/-, CD3- LRCHL 
F 2001 NLPHL CD20-, CD30+, CD15+, CD3- LRCHL 
M 1984 NLPHL CD20-, CD30+, CD15+, CD3- cHL NOS 
M 1977 HL NOS CD20+, CD30-, CD15-, CD3- NLPHL 
M 1991 NLPHL with spelling error 
and MCCHL 
CD20+, CD30-, CD15-, CD3- NLPHL 
M 2005 LDCHL CD20+, CD30-, CD15-, CD3- DLBCL 
M 1982 Tumor malignum, possibly 
HL NOS 
CD20-, CD30-, CD15-, CD3- Malignant tumor 
NOS 
M, male; F, female 
3.5 The SIR for NLPHL on the basis of histopathologically verified cases 
In the histopathological review of the tumor samples, NLPHL diagnosis was verified for altogether 
nine first-degree relatives. Thus, the SIR for NLPHL was 19 (95% CI 8.8-36). In male relatives, the 
SIR was 14 (95% CI 4.6-33) and in female relatives, it was 33 (95% CI 9.1-85). In the relatives of 
early-onset patients, the SIR for NLPHL was 38 (95% CI 7.7-110). In male relatives of early-onset 
patients the SIR was 14, but the result was not statistically significant, and in female relatives, the SIR 
was 100 (95% CI 12-361). In the relatives of late-onset patients, the SIR was 15 (95% CI 5.7-33). In 
male relatives of late-onset patients, the SIR was 14 (95% CI 3.9-37) and in female relatives, the SIR 




4. Familial PMBCL (IV) 
In Family 2, the clinical information and histological examination of tumor samples confirmed the 
diagnosis of PMBCL in cases 1-3 (Figure 4). In addition, the tumor of case 4 displayed similar 
histopathological features. The tumors of all four patients expressed CD20, CD30, IRF4/MUM1, 
BCL6, PAX5, OCT2 and BOB1, but did not express CD10, CD23 and LMP1. BCL2 expression was 
moderate-low, and in three tumors, Reed-Sternberg-like cells were observed. These factors implicated 
a common biological background in all cases, with post germinal center differentiation and 
susceptibility to apoptosis. Family 2 is, as far as we know, the first identified case of familial PMBCL. 
The clinical features of all lymphoma patients in Family 2 are summarized in Table 15. 
Table 15. The clinical features of lymphoma patients in Family 2 (Figure 4). 
Individual             
(as in Figure 4) 





Case 1 Vena cava 
syndrome 
Mediastinum no PMBCL  IA 
Case 2 Lymphadenopathy Mediastinum no PMBCL IIIB 
Case 3 Fatigue and weight 
loss 
Mediastinum no PMBCL IVB 










4.1 Linkage analysis and exome sequencing 
In Family 2 (Figure 4), linkage analysis with a dominant model identified sixteen segregating 
genomic loci, which spanned at least 5cM and had a positive LOD score. The linked regions are 
shown in Table S3 in the original publication. The exomes of cases 1 and 3 (Figure 4) were 
sequenced, with the average coverage of 47 reads and 22 reads, respectively. In both cases, over 90% 
of the targeted regions were covered with at least two reads. The patients shared altogether 2260 non-
silent exome variants. The variants were then compared with dbSNP132 and 1000 genomes databases 
and 196 control exomes, and all variants found in databases or controls were removed. Only three 
variants remained, and of these, only two were located in the linked regions. These two heterozygous 
variations were c.5533C>A (His1845Asn) in MLL and c.1870C>T (Pro624Ser) in SORL1. Both 
variations were validated by direct sequencing (Figure 6), however, only the MLL sequence change 







Figure 6. The MLL and SORL1 variations in Family 2 identified by combining linkage analysis and 
exome sequencing. 
4.2 In silico prediction 
The effect of both detected variants on protein function was predicted by using PolyPhen2. MLL was 
predicted to be possibly damaging with a score of 0.842 (sensitivity 0.83 and specificity 0.93) and 
SORL1 c.1870C>T was predicted as probably damaging with a score of 1.000 (sensitivity: 
0.00; specificity: 1.00). 
 
4.3 Screening of MLL 
The MLL c.5533C>A variant was the only variant segregating in all four patients in Family 2 (Figure 
4), thus making MLL a candidate gene for lymphoma predisposition in this family. Hence, MLL was 
further studied from the available sample material.  
The MLL c.5533C>A was analyzed in the tumor samples of cases 1-4 (Figure 4), but loss of 
heterozygosity was not observed. Three healthy family members, that is, the mother of cases 1-3 and 
two healthy children of case 2, were also found to be carriers of the variation. However, the variant 
was not found in any of the 86 screened healthy controls.  
The MLL c.5533C>A variant is surrounded by two predicted domain regions: a proline-rich region 
(PS50099) spanning the amino acids 1820-1868, predicted by the PROSITE database (Sigrist et al. 
2010), and a low complexity region spanning the amino acids 1820-1854, predicted by the SEG tool 
(Wan & Wootton 2000, Wootton 1994), which is available in the Pfam database (Finn et al. 2010). 
Thus, these predicted domains were screened in the validation material (Materials and methods 1.2). 
Other non-silent mutations of MLL were not detected, implying that the role of MLL in PMBCL 











In 2011, approximately 30 000 new cancers were diagnosed in Finland, and over 11 000 individuals 
died of cancer (www.cancerregistry.fi). Although inherited susceptibility underlies only a fraction of 
cancers, the research on inherited cancer susceptilibity has led to the discovery of many genes, 
pathways and molecular mechanisms which are important in the pathogenesis of both hereditary and 
sporadic cancers (Fletcher & Houlston 2010). Understanding the genetic background, biology and 
characteristics of cancer is important for the development of new targeted and personalized therapies 
and diagnostic tools. In addition, clinical characterization of cancer susceptibility and identification of 
underlying genetic defects enables the genetic counseling of family members, predictive genetic 
testing and appropriate surveillance and interventions for individuals who are at increased risk of 
developing cancer. 
Traditionally, research on inherited genetic disorders has been successful in Finland. One reason for 
this is the excellent registry infrastructure. Today, the Population Registry Center covers the whole 
population, and the Church Parish Registers extend to the 17
th
 century. Thus, extensive genealogy 
work is possible and ancestors can be traced back many generations. Due to Finland’s population 
history, some rare genetic diseases, such as those belonging to the “Finnish Disease Heritage”, have 
enriched into the Finnish population, and the population registers have played an important role in the 
study of these diseases (Norio 2003). Cancer research is largely facilitated by the Finnish Cancer 
Registry, which has been founded in 1952, and which covers almost all cancers diagnosed in Finland 
(Teppo et al. 1994). Importantly, the Finnish legislation allows the use of these registries in medical 
research, and in many cases, Finnish patients are willing to participate in research projects. 
1. Genetic basis of familial NLPHL  
The genetic alterations underlying the pathogenesis of Hodgkin lymphoma, and particularly NLPHL, 
are still mostly unclear. Research on the genetics of HL is hampered by the scarcity of malignant cells 
in the tumor tissue which makes it challenging to obtain tumor-derived DNA. Many studies have 
previously used HL derived cell lines, however, a recent study showed that the gene expression 
profiles of microdissected HRS cells and HL cell lines are different (Tiacci et al. 2012). In addition, 
only one NLPHL-derived cell line exists (Atayar et al. 2006). Thus, cell lines may not be the ideal 
model to study the biology of HL. Identification of susceptilibity genes for familial NLPHL might 
reveal new pathways and mechanisms that are important in the pathogenesis of the disease. A better 
understanding about the biology of NLPHL may enable, for example, the development of better 
diagnostic tools, the identification of biomarkers and more personalized approaches for choosing 
treatment.  
1.1 Characteristics of familial NLPHL (I) 
NLPHL has been estimated to account for about 5% of HL, and the proportion of different subtypes 
of HL has been reported to be similar in familial and non-familial cases (Ferraris et al. 1997). As 
familial cases have been estimated to represent 4.5% of HL (Kerzin-Storrar et al. 1983), familial 
NLPHL is presumably very rare. In fact, only four reports describing familial clustering of NLPHL 
were found in the literature (Bauduer et al. 2005, Campbell et al. 2004, Unal et al. 2005, Ur Rehman 
et al. 2008). The newly identified Finnish family, Family 1 (Figure 4), is thus the largest NLPHL 
family described with four affected relatives.  
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Factors implicating inherited susceptibility to cancer include, for example, more than one relative with 
the same cancer type, especially a rare cancer, many affected generations and early age of cancer 
onset (Nagy et al. 2004). In Family 1, four maternal cousins all have NLPHL, a rare cancer, and they 
have all been diagnosed at a younger age than is typical for NLPHL. These factors suggest an 
inherited predisposition. However, the mothers of all four cousins are healthy, which makes it 
challenging to evaluate the mode of inheritance in Family 1. Thus, the clustering of NLPHL in Family 
1 may be due to a dominantly inherited genetic factor with a reduced penetrance, a recessively 
inherited factor, or a genetic defect residing in an imprinted region or mitochondrial DNA. However, 
autosomal dominant model is the only one that fits all reported NLPHL families, as in the UK/India 
family two siblings are affected (Campbell et al. 2004), in the French family the affected individuals 
are a father and two sons (Bauduer et al. 2005), the Turkish family includes an affected mother and 
son (Unal et al. 2005), and in the Omani kindred the affected relatives are half-brothers (Ur Rehman 
et al. 2008). On the other hand, as the risk factors of NLPHL are unknown, familial clustering of 
NLPHL due to environmental or multigenic factors cannot be excluded.  
1.2 Germline mutations of KLHDC8B were not detected in familial NLPHL (I) 
Familial HL is a well-known disorder, however, despite intensive study, only few candidate 
predisposing genetic factors have been identified. Germline mutations in KLHDC8B have been 
reported to be associated with cHL in four families (Salipante et al. 2009). Originally, a translocation 
leading to the disruption of KLHDC8B was identified in a family which included three siblings 
affected by NSCHL and a mother with an uncharacterized mediastinal tumor, and subsequently a 
heterozygous variation in the 5’UTR of the gene was found in three families with cHL. KLHDC8B is 
a protein of seven kelch domains, and functional studies suggested that its depletion increases the 
number of binucleated cells, such as Reed-Sternberg (RS) cells in cHL (Salipante et al. 2009).  
NLPHL and cHL are considered as separate disease entities; however, on the basis of gene expression 
studies, they seem to be related (Brune et al. 2008, Tiacci et al. 2012). Thus, in this study, the 
KLHDC8B gene was screened in four NLPHL families to decipher whether the same candidate gene 
underlies the predisposition to both subtypes of HL. Germline mutations associated with NLPHL 
were not found, suggesting that genetic variations in KLHDC8B do not contribute to NLPHL 
susceptibility. Indeed, the exclusion of KLHDC8B as a candidate gene for familial NLPHL is not 
unexpected, as in NLPHL the malignant cells are usually mononuclear, whereas KLHDC8B was 
implicated in the formation of binuclear RS cells (Salipante et al. 2009). In addition, in the original 
family described by Salipante et al. (2009), three affected family members had NSCHL, whereas 
expression studies have suggested that the LRCHL and MCCHL subtypes are closest to NLPHL, 
whereas NSCHL resembles more PMBCL (Tiacci et al. 2012).  
1.3 Exome sequencing and linkage analysis in the detection of susceptibility genes in hereditary 
disorders (II) 
As the analysis of KLHDC8B did not reveal genetic defects underlying NLPHL in Family 1 (Figure 
4), the genetic studies were continued with exome sequencing and linkage analysis. Exome 
sequencing is a massive parallel sequencing technique which enables the systematic sequencing of the 
coding regions of the genome cost-effectively. In recent years, it has been widely and successfully 
used to detect causative mutations in many genetic diseases. The first Mendelian disorder whose 
genetic basis was clarified by utilizing exome sequencing was the Miller syndrome (Ng et al. 2010b), 
and subsequently, exome sequencing efforts have indeed revealed underlying genes in the background 
of many genetic disorders, including some cases of hereditary predisposition to tumors (Table 16). 
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The limitations of exome sequencing include imperfect coverage and capture of all exons, sequencing 
errors, and the fact that all genes are not included in all exome capture arrays (Choi et al. 2009, Ku et 
al. 2011, Pasqualucci et al. 2011, Zhi & Chen 2012). In addition, exome sequencing platforms do not 
usually cover regulatory regions, promoter regions and non-coding RNAs, which may be important in 
some diseases, and structural variations and chromosomal rearrangements can not be detected (Ku et 
al. 2011). Thus, in the future, whole-genome sequencing, which can provide more comprehensive 
information about the genome, will likely replace exome sequencing.  
Linkage analysis can be used to detect genomic regions segregating with a phenotype. It is a more 
traditional method than next-generation sequencing technologies, and it has been largely used for 
example as a part of positional cloning approaches and in combination with gene expression data to 
identify genes underlying hereditary diseases (Botstein & Risch 2003, Vierimaa et al. 2006). It is 
most suitable for the detection of alleles which confer a high risk of a disease but which are rare in the 
population (Bailey-Wilson & Wilson 2011). The limitations of linkage analysis include, for example, 
the fact that it requires large pedigrees with enough informative meiosis to obtain statistically 
significant results and that the identified genomic regions are usually large and contain several genes 
(Wijsman 2012). 
Table 16. Genetic disorders in which the causative factor has been identified by using exome 
sequencing. 
Disorder Identified gene Reference 
Familial pancreatic cancer PALB2 (Jones et al. 2009) 
Miller syndrome DHODH (Ng et al. 2010b) 
Kabuki syndrome MLL2 (Ng et al. 2010a) 
Hereditary pheochromocytoma MAX (Comino-Mendez et al. 2011) 
Familial meningioma 
predisposition 
SUFU (Aavikko et al. 2012) 
Nocturnal frontal lobe epilepsy KCNT1 (Heron et al. 2012) 
Leber congenital amaurosis NMNAT1 (Chiang et al. 2012, Falk et al. 
2012) 
Familial thoracic aneurysms TGFB2 (Boileau et al. 2012) 
Actinic porokeratosis MVK (Zhang et al. 2012) 
 
1.4. Identification of NPAT as a candidate gene for familial NLPHL (II) 
In study II, the exome of only one NLPHL-affected individual was sequenced, which resulted in the 
list of over 7000 potential variants residing in the protein coding parts of the genome. The number of 
candidate variants was narrowed down by focusing to linked regions, removing database variants and 
using thirteen control exomes. After these procedures, fourteen putative variants remained, and half of 
them were found to be sequencing errors. On the other hand, it is impossible to estimate how many 
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variants were not identified due to the limitations of the methodology. In addition, our approach 
(exome sequencing) did not consider variants in the non-coding parts of the genome and could not 
detect structural variants. 
After segregation analysis of the seven verified (true positive) variants and sequencing of healthy 
controls, a heterozygous c.2437-2438delAG variation in NPAT was identified in Family 1. The 
variation deletes two basepairs, and thus leads to frameshift and a premature stop codon in NPAT. In 
many cases, mRNAs with a premature stop codon are degraded by the nonsense-mediated mRNA 
decay (NMD) pathway (Baker & Parker 2004). The expression of NPAT in blood was reduced in the 
mutation carriers, suggesting that the mutation affects the levels of NPAT mRNA and that the mRNA 
from the mutated allele is possibly directed to NMD. In addition to the NLPHL patients and obligate 
carriers in Family 1, the NPAT c.2437-2438delAG variation was detected in three healthy family 
members. This, however, does not exclude NPAT as a candidate gene for NLPHL susceptibility in 
Family 1, as it is common that cancer predisposition syndromes display reduced penetrance (Nagy et 
al. 2004). Most genes identified to cause familial cancer predisposition are tumor suppressors 
(Knudson 2002), and in many cases, a “second hit” mutation can be observed in the tumor tissue. As 
the tumor tissue in NLPHL contains only very small proportion of malignant cells, it was not feasible 
in study II to investigate whether a second hit affecting the other allele of NPAT occurs in the cancer 
cells.   
In the validation material, a deletion of serine 725 in NPAT was detected in seven patients with HL, 
and the statistical analysis yielded an odds ratio of 4.11 for the association of the variant with HL. 
One of the seven patients with the deletion had early-onset NLPHL. For the other six patients, the HL 
subtype was not available, and thus, it is not possible to conclude whether NPAT germline variations 
underlie specifically NLPHL. It is however noteworthy that all cases harboring the serine 725 deletion 
were either young individuals, or individuals with a family history of lymphomas. Interestingly, in 
most cancers these factors point towards a predisposing genetic factor.  
In recent years, the number of database variations has increased enormously, largely due to the 1000 
Genomes Project (1000 Genomes Project Consortium 2010), and at present, deletion of serine 725 in 
NPAT (rs141989202) can be found in the databases with a minor allele frequency (MAF) of 0.01 
(www.ensembl.org). Rare variants conferring a moderate (over 2-fold) cancer risk typically have a 
MAF of 2% or less (Fletcher & Houlston 2010). Thus, the increased odds ratio for the serine 725 
deletion as well as the reported MAF are both compatible with a rare variant causing moderate cancer 
risk. Nevertheless, the number of HL cases as well as healthy controls was small in study II, and thus, 
a larger dataset would be needed for a more reliable estimation.  
1.5 NPAT (II) 
The NPAT (previously also named as E14) gene was originally identified to reside next to the ATM 
gene in the chromosomal region 11q22-q23 (Byrd et al. 1996, Imai et al. 1996). The two genes are 
separated by only about 500 basepairs, and are transcribed in opposite directions. Imai et al. also 
suggested that the genes may share regulatory elements and affect each other’s expression, and a 
shared promoter region was also proposed by Byrd et al. NPAT was reported to be expressed in many 
tissues, and the gene was designated as a housekeeping gene implicated in cell-cycle regulation (Byrd 
et al. 1996, Imai et al. 1996). NPAT was also found to consist of 18 exons and to encode a protein of 
1427 amino acids (Imai et al. 1996, Imai et al. 1997).  
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The functions of NPAT were illuminated in further studies. Zhao et al. (1998) reported that NPAT is a 
phosphorylation substrate of cyclin E-CDK2 and its expression reaches its highest point when the cell 
is entering from G1 to S phase (Zhao et al. 1998). They demonstrated that overexpression of NPAT 
stimulated cells to enter the S-phase, particularly when cyclin E-CDK2 was coexpressed, suggesting a 
role for NPAT in cell cycle regulation. NPAT was also reported to interact with CBP/p300 to enhance 
the entry to S phase, even in a CDK2-independent manner (Wang et al. 2004). In addition, the 
expression of NPAT was shown to be stimulated by E2F, and this interaction was necessary for the 
transition from G1 to S phase (Gao et al. 2003).  
The cyclin E-CDK2 is an enzyme which has a central role in the progression of a cell from G1 to S 
phase, and its activity is highest in cells at the time of this transition (Hwang & Clurman 2005). The 
cyclin E-CDK2 activation is regulated by the RB-E2F and Myc pathways, which are both implicated 
as important factors in the control cell proliferation (Bartek & Lukas 2001) and which are frequently 
deregulated in cancer (Secombe et al. 2004, Sherr 2000). The downstream effects of cyclin E-CDK2 
are mostly mediated by the phosphorylation of its substrates, which, in addition to NPAT, include for 
example RB, p27 and CPB/p300 (Hwang & Clurman 2005). Overexpression of cyclin E is common in 
many cancers, including lymphomas, and is most often caused by the aberrant functions of the 
regulatory pathways (Erlanson et al. 1998, Hwang & Clurman 2005). Cyclin E overexpression has 
also been suggested to contribute to carcinogenesis via causing genomic instability (Hwang & 
Clurman 2005).      
After recognition of NPAT as a cyclin E-CDK2 substrate, subsequent studies showed that during S 
phase, NPAT is associated with the histone gene clusters on chromosomes 1 and 6, and that the 
phosphorylated NPAT stimulates histone gene transcription which occurs in the S-phase (Ma et al. 
2000, Zhao et al. 2000). Thus, these studies connected the cyclin E-Cdk2 related cell cycle regulation 
with histone gene expression. The H4 gene transcription factor HiNF-P and the TRRAP-Tip60 
complex have been characterized as interaction partners which function together with NPAT to induce 
histone gene transcription by activating the histone gene promoters (DeRan et al. 2008, Miele et al. 
2005). In addition, HiNF-P was shown to regulate other target genes, such as ATM, PRKDC and 
CKS2, and the HiNF-P/NPAT complex was found to activate the promoters of both NPAT and ATM 
(Medina et al. 2007). 
The possible connection between NPAT and ATM regulation is an intriguing idea, considering that in 
study II the individuals carrying NPAT germline mutations are affected by lymphoma, whereas 
germline mutations of ATM are the cause of ataxia-telangiectasia (OMIM 208900), a recessively 
inherited syndrome in which the affected individuals are at increased risk of lymphomas and 
leukaemias (Garber & Offit 2005). In ataxia-telangiectasia,  the lymphomas are usually B-cell derived 
and leukaemias T-cell derived, and other clinical features include cerebellar ataxia, which typically 
occurs in childhood, telangiectases, (dilated superficial blood vessels), immune deficiency and 
susceptibility to infections, and a high risk of cancer in general (http://www.ncbi.nlm.nih.gov/omim). 
An increased cancer risk has also been observed in heterozygous carriers of ATM mutations (Swift et 
al. 1987). The cancer risk in ataxia-telangiectasia is thought to result from genomic instability caused 
by deficient DNA repair mechanisms, since ATM normally mediates response to DNA damage 
(Mavrou et al. 2008).    
Only a few previous studies have implicated NPAT in cancer. Kalla et al. (2007) reported reduced 
expression of NPAT in B-cell lymphomas harboring deletion of 11q22-q23; however, sequence 
analysis did not reveal additional deleterious mutations (Kalla et al. 2007). Mishra et al. (2010) 
observed hypermethylation of NPAT as well as promoter methylation in prostate cancer cell lines 
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(Mishra et al. 2010). The deletions encompassing the chromosomal region 11q22-23 have been 
reported in many B-cell malignancies, including chronic lymphocytic leukaemia (CLL), mantle cell 
lymphoma and Hodgkin lymphoma (Klein & Dalla-Favera 2010, Monni et al. 1998, Steidl et al. 
2010). However, in both B-CLL and mantle cell lymphoma, sequence analyses of cases displaying the 
deletion have detected both germ line and somatic mutations in the ATM gene residing in this region 
thus suggesting that ATM is the most likely candidate gene in this region (Bullrich et al. 1999, 
Schaffner et al. 1999, Schaffner et al. 2000). 
1.6 NPAT and susceptibility to NLPHL (II) 
In study II, NPAT was identified as a candidate gene for familial NLPHL. The most important known 
functions of NPAT are related to the cell cycle and transcription of histone genes. On the one hand, 
NPAT is a component of an important machinery controlling critical steps in the regulation of cell 
proliferation, and many effectors functioning upstream of NPAT have been associated with cancer 
(Bartek & Lukas 2001, Hwang & Clurman 2005, Secombe et al. 2004, Sherr 2000, Zhao et al. 1998). 
On the other hand, NPAT is involved in the histone gene transcription in the S-phase, the cellular 
phase during which DNA is replicated (Ma et al. 2000, Zhao et al. 2000). In addition, the regulation 
of NPAT may be connected to and/or with ATM (Byrd et al. 1996, Imai et al. 1996, Medina et al. 
2007). Thus, there are many possible mechanisms and pathways which may link NPAT mutations to 
cancer. However, truncating NPAT germline mutations were found to segregate with NLPHL in only 
one family, and an in-frame deletion of one amino acid was found in a handful of other HL cases, 
whereas in the additional analyzed NLPHL families mutations of NPAT were not detected. These 
results suggest that while NPAT is an interesting candidate gene for NLPHL predisposition, genetic 
and/or functional validation for the association of NPAT mutations and HL is needed from future 
studies.  
2. NLPHL risk in the first-degree relatives of patients  
NLPHL is a rare lymphoma and, likely due to its rarity, its risk factors are largely unknown and 
epidemiological studies are lacking. The identification of Family 1 and NPAT as a candidate gene for 
NLPHL prompted us in study III to evaluate the familial risk of NLPHL in a large, population-based 
cohort of first-degree relatives of patients with NLPHL. The step-wise strategy used in this study is 
shown in Figure 7.  
2.1 Identification of NLPHL patients  
The first step in the study was to identify patients with NLPHL from the FCR. The identification of 
NLPHL patients was done by using keyword-based searches. Indeed, the large-scale and population-
wide identification of NLPHL patients was possible due to the FCR, which has been estimated to 
cover almost all cancers in Finland (Teppo et al. 1994). However, as before 2006 HL subtypes have 
not been coded separately in the FCR database system, keywords were used to find the NLPHL 
diagnoses. We identified altogether 693 patients with NLPHL diagnosis, and they were used as 
probands for the genealogy work. These patients were also re-coded into “NLPHL” category in the 
FCR for the calculation of SIRs.  In 1980-2008, NLPHL represented an average of 16.6% of all HL 
cases in Finland. The high NLPHL/HL ratio suggests that the keyword searches have likely identified 
most patients diagnosed with NLPHL after 1980. However, some NLPHL cases have probably been 
missed, for example cases where the FCR notification has included unusual terms which did not 
match our keywords or cases where the FCR notification has included spelling errors. The low 
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NLPHL/HL ratio before 1980 suggests that information on the specific HL subtypes was not as 
frequently available in the FCR before 1980 as after it.       
 
Figure 7. The strategies that were utilized for the calculation of the standardized incidence ratios for 
NLPHL and other cancers in the first-degree relatives of patients with NLPHL. FCR, Finnish Cancer 
Registry. 
The differential diagnoses of NLPHL include LRCHL and TCRBCL (Lee & LaCasce 2009). 
Classification of lymphoid malignancies has changed during the years, and the histopathological 
diagnosing of lymphomas is challenging, as characterized by a recent study which observed a 
discordance rate of 27.3% in lymphoma diagnoses when expert central review was applied (Proctor et 
al. 2011). Lymphocyte-rich subtype of cHL was first introduced as a “provisional entry” in 1994 by 
the International Lymphoma Study Group, and as a distinction from NLPHL, it was suggested to 
display the morphology and immunophenotype of HRS cells (Harris et al. 1994). Subsequently, the 
LRCHL subtype was more firmly established by the European Task Force on Lymphoma project 
studies (Anagnostopoulos et al. 2000, Diehl et al. 1999). These studies also reported that 




In study III, the observed NLPHL/HL ratio was clearly higher than what has been reported previously. 
There are several factors that probably underlie this observation. First, our series likely include cases 
of LRCHL, which have been suggested to comprise about one third of older NLPHL cases 
(Anagnostopoulos et al. 2000, Diehl et al. 1999). Second, misdiagnosing is common in lymphoid 
malignancies in general (Proctor et al. 2011). Third, fourteen percent of the identified 693 patients 
with NLPHL diagnosis in the FCR had been diagnosed with some other HL subtype as well, 
implicating that the diagnosis has not been clear. Thus, a fraction of the 693 patients with NLPHL do 
not probably fulfill the current diagnostic criteria for NLPHL. On the other hand, the age and sex 
distribution of the patients in our dataset is similar to previous observations on NLPHL, suggesting 
that our dataset represents NLPHL as much as is possible considering the previously mentioned 
limitations. In addition, 55% of the NLPHL diagnoses in our dataset had been settled by a 
hematopathologist, and recent cancer statistics from the Finnish Cancer Registry have reported that 
NLPHL accounts for 11% (2008) - 16% (2009) of HL in Finland (Finnish Cancer Registry, 2011), 
proposing that NLPHL may be a relatively common HL subtype in Finland.  
2.2 Relative cancer risk in the first-degree relatives  
After the identification of 693 patients with NLPHL, the family member cohort was collected by 
utilizing the Population Registry Center and Church Parish Registers. The relatives of all except one 
NLPHL case were systematically identified, which demonstrates the excellent utility of the registry 
infrastructure. After exclusion of those relatives who were not alive or living in Finland during the 
follow-up, a family member cohort of 4126 individuals remained for the statistical analysis. The 
relative cancer risk, the SIR, was first calculated by using the diagnoses available in the FCR.  
A 3-4-fold relative risk of HL has been previously reported in the first-degree relatives of HL patients 
(Goldin et al. 2004, Goldin et al. 2009). In addition, increased relative risks of DLBCL (2.45-fold), 
NHL (1.26-fold) and any lymphoproliferative disorder (1.65-fold) have been described in the same 
studies. In study III, the overall relative cancer risk in the relatives of NLPHL patients was slightly 
increased to 1.1-fold, which may reflect the increased incidence of lymphoid cancers in the relatives 
of patient with HL. The risk of NHL was increased to 1.9-fold. Histologically, NLPHL resembles 
TCRBCL, a subtype of DLBCL, and a possible overlap between the diseases has been proposed 
(Swerdlow et al. 2008 p.323). Relatedness of these two diseases has also been suggested on the basis 
of gene expression profiling (Brune et al. 2008). In addition, a fraction of NLPHL cases transform to 
DLBCL (Al-Mansour et al. 2010, Biasoli et al. 2010). Thus, a part of the NHL affected relatives may 
have DLBCL or TCRBCL, and it could be envisioned that shared etiological factors contribute to 
both NLPHL and DLBCL in these families. On the other hand, as lymphomas are often diagnosed 
incorrectly (Proctor et al. 2011) and as NLPHL shares features with TCRBCL (Swerdlow et al. 2008 
p.323), it is possible that the relatives with NHL diagnosis include some cases of NLPHL. 
In the first-degree relatives, the SIR for cHL was 5.3. This category included all relatives with HL 
diagnosis in the FCR except cases who had been classified in the NLPHL-category on the basis of the 
keyword search. Thus, in addition to cHL, the category included relatives with HL NOS diagnosis. 
Male relatives had a slightly more increased risk (6.0-fold) compared with females (4.7-fold). 
Similarly, in a previous study reporting on relative HL (all subtypes included) risk in the first-degree 
relatives of patients, a higher HL risk in the male relatives was observed (Goldin et al. 2004). In the 
study by Goldin et al. (2004) the relative risk of HL was also highest in the relatives of young (< 40 
years) HL patients. However, in study III, the SIR for cHL in the relatives of early onset patients was 
not statistically significant. The registry-based SIR for NLPHL was 26, and the relative risk was 
clearly higher in female relatives (48-fold) than male relatives (17-fold). Although in the subsequent 
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stages of the study the original diagnoses of all relatives with NLPHL were not confirmed, the 
registry-based SIR should still be a good estimate of the relative risk as in this approach, the observed 
and expected number of cases is calculated in the most standardized way. The FCR-based cumulative 
incidences of NLPHL, HL and all lymphomas were 0.6%, 1.3% and 3.4%, respectively.  
The registry-based SIRs suggest that the first-degree relatives of NLPHL patients have an increased 
risk for NLPHL, HL and all lymphomas. Although the relative risk is highest in NLPHL, implicating 
that the familial cases may have predisposing factors which are subtype-specific, the lifetime risk of 
NLPHL in the first-degree relatives is very small. The elevated relative risk for NHL and cHL in the 
first-degree relatives suggests that these other lymphoma types and NLPHL may, however, have some 
common risk factors. Although the cumulative incidence, which reflects the lifetime risk, of all 
lymphomas in the first-degree relatives is not substantial, the risk of 3.4% is still noteworthy. 
2.3 Histopathological examination  
We were able to collect primary tumor biopsies from 10/12 first-degree relatives with NLPHL 
diagnosis and from 10/15 relatives with some other HL diagnosis in the FCR. In the histopathological 
examination of the samples derived from the relatives with NLPHL diagnosis, three cases were found 
to represent cHL. This rate is fairly similar to previous reports on discordance rates or slightly less 
(Anagnostopoulos et al. 2000, Diehl et al. 1999, Proctor et al. 2011). Our result that 2/3 of these cases 
represented LRCHL is also compatible with the literature and is not surprising, as NLPHL and 
LRCHL often display similar histopathological features (Eberle et al. 2009). In addition, these two 
subtypes are close to each other on the basis of gene expression (Tiacci et al. 2012). One relative with 
NLPHL diagnosis from whom biopsy material was available only from a relapse 10 years after the 
diagnosis was found to have TCRBCL. As NLPHL and TCRBCL are considered related or possibly 
overlapping diseases (Swerdlow et al. 2008 p. 323) and as secondary NHLs following NLPHL are 
relatively often TCRBCL (Rudiger et al. 2002), it is possible that this relative originally had NLPHL.  
In addition to the seven confirmed relatives with NLPHL diagnosis, two first-degree relatives who 
were not originally identified as NLPHL cases were found to have NLPHL in the histopathological 
examination. Thus, NLPHL was verified for altogether nine first-degree relatives of whom four were 
women and five were men. The SIR for NLPHL was estimated on the basis of these nine cases and 
was found to be 19. Women had a higher relative risk (33-fold) than men (14-fold), and female 
relatives of young patients displayed the highest relative risk (100-fold). As NLPHL is generally most 
common in men who are older than 30 years (Swerdlow et al. 2008 p. 323), the high risk in women 
may in part be due to the fact that the expected risk is much lower in women. Nevertheless, the high 
familial risk in NLPHL suggests that familial factors, such as inherited or environmental, contribute to 









3. Familial PMBCL 
3.1 Clinical features in familial PMBCL  
PMBCL is an uncommon non-Hodgkin lymphoma comprising about 2-4% of NHL cases (Swerdlow 
et al. 2008 p. 250). Its risk factors are unknown (Martelli et al. 2008). In study IV, Family 2 with 
predisposition to PMBCL was characterized. Examination of medical records confirmed clinical 
features associated with PMBCL in cases 1-3, as all three patients had a mediastinal tumor mass, but 
infiltration to bone marrow was lacking. The age-of-onset of these patients (30-46 years) as well as 
their symptoms, such as vena cava syndrome, fatigue and weight loss, are also typical in PMBCL 
(Swerdlow et al. 2008 p. 250). The histopathological review of tumor samples from cases 1-4 
revealed similar features in all tumors. These features included post germinal center characteristics 
and low BCL2 expression implicating that other mechanisms than inhibition of apoptosis by BCL2 
underlie the deregulated growth in the tumors. The immunophenotypes of tumors from cases 1-3 were 
compatible with PMBCL, thus establishing the diagnosis for these cases. In sum, the similarity of all 
four tumors implicates a common biological background. The identification of Family 2 suggests that 
genetic or other familial factors may play a role in some PMBCL cases, and thus, patients with 
PMBCL should be interviewed for family history. Identification of other PMBCL families will enable 
the better clinical characterization of this phenotype.  
3.2 Identification of MLL as a candidate gene in Family 2  
The pedigree of Family 2 (Figure 4) is most compatible with dominant inheritance. Thus, dominant 
model of inheritance was used in the linkage analysis, which resulted in the identification of sixteen 
candidate regions. Exome sequencing of cases 1 and 3 yielded thousands of variants. However, the 
comparison of these two exomes to each other, and filtering of variants against databases and control 
samples, excluded the majority of exome variants. After filtering procedures and integration of exome 
and linkage data, two variants were identified: c.5533C>A (His1845Asn) in MLL and c.1870C>T 
(Pro624Ser) in SORL1. However, subsequent sequencing efforts revealed that the SORL1 variant did 
not segregate in the four lymphoma-affected members of Family 2. The MLL c.5533C>A variant, 
located in exon 19, was predicted as possibly damaging, and was studied in the tumor samples of 
cases 1-4; however, loss-of-heterozygosity (LOH) was not detected. Although in classical examples 
LOH is often detected in tumor suppressor genes, sometimes haploinsufficiency may be enough to 
induce cancer development (Berger et al. 2011, Santarosa & Ashworth 2004). On the other hand, the 
tumors may harbor other kinds of second hits than LOH, such as point mutations or methylation, or 
the MLL c.5533C>A variant may be a gain-of-function variant or affect the regulation of MLL.  
MLL is a histone methyltransferase which contributes to gene regulation by introducing methyl 
groups into histone proteins (Ansari & Mandal 2010). In addition, MLL and other genes of the MLL 
group regulate the HOX genes, which are important in development, and act as general regulators of 
transcription. MLL also contributes critically into the maintenance of hematopoietic stem cells, and 
enhances the proliferation of progenitor cells (Jude et al. 2007). MLL is a large gene spanning 36 
exons and encoding a protein of 3969 amino acids (Daser & Rabbitts 2004). Chromosomal 
translocations involving MLL, which resides on chromosome 11q23, are common in leukaemias, such 
as leukaemias of infants, adult AMLs and therapy related leukaemias (Krivtsov & Armstrong 2007). 
The chromosomal breakpoint occurs in most cases in the breakpoint cluster region which 
encompasses exons 8-13, and the translocations lead to the fusion of the N terminus of MLL with 
over 50 translocation partners. The methyltransferase activity of MLL is disrupted due to the 
translocations, and most translocations seem to cause elevated expression of MLL target genes, such 
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as the HOX genes (Krivtsov & Armstrong 2007). In addition to leukaemias, mutations of MLL have 
been recently identified in the background of Wiedemann-Steiner syndrome (MIM 605130), as Jones 
et al. (2012) reported five individuals with harboring germline de novo mutations of MLL that lead to 
truncated protein and NMD (Jones et al. 2012).  
The MLL c.5533C>A variant identified in Family 2 resides in exon 19 and, thus, in a region which is 
deleted from MLL fusion proteins. The variant is located inside two predicted domain regions: a 
proline-rich region (PS50099) and a low complexity region. Although the functions of these putative 
domains have not been established, proline-rich regions have in general been implicated in protein 
interactions (Kay et al. 2000). The predicted domain regions also reside between the MLL 
bromodomain and the PHD-like zinc binding/PHD4 domain (Figure S1, study IV). The region 
spanning these two established domains was recently shown to mediate the interaction of MLL with 
ASB2, which, in turn, mediates the degradation of MLL and down-regulation of its target genes 
(Wang et al. 2012). Thus, it could be speculated that the MLL c.5533C>A variant may affect some 
interactive or regulatory functions of MLL and thus confer increased susceptibility to PMBCL.  
In study IV, we have identified a missense mutation in the MLL gene segregating with PMBCL in 
Family 2. The MLL c.5533C>A variant was the only non-silent and non-database variation as 
identified by exome sequencing. Additional MLL mutations residing in the studied putative domain 
regions were not detected in our validation set. However, the validation set included only one sporadic 
case of PMBCL (Table S1, study IV), whereas all other cases represented other subtypes of NHL. In 
addition, the sequencing of the whole MLL gene was not, due to the gene’s large size, feasible in 
study IV, and therefore it is possible that some cases in the validation set harbor variations in other 
parts of the MLL gene. Although we have identified MLL as a candidate gene for familial PMBCL 
susceptibility, the association of MLL variations and PMBCL needs to be validated in other studies. 
Therefore, identification of new PMBCL families would be important, to enable better clarification of 
the genetic background of the disease.  
4. Genetic counseling in families with lymphoma susceptibility 
Genetic counseling is a process which includes the genetic risk assessment, communication about the 
risk to the counselee, possible genetic testing and evaluation about whether preventive interventions 
or screening are needed. As high risk cancer susceptilibity is estimated to underlie 5-10% of all 
cancers (Nagy et al. 2004) cancer patients should be carefully interviewed for family history. Hampel 
et al. (2004) have proposed that in addition to well-known cancer susceptibility syndromes, high-risk 
cancer susceptibility should be suspected when three cases of the same cancer occurs in first-degree or 
second-degree relatives. In these families, family members would benefit from genetic counseling and 
cancer surveillance (Hampel et al. 2004). 
The observations and results presented in this work suggest that genetic susceptibility may underlie 
some cases of NLPHL and PMBCL. In addition, some established cancer susceptibility syndromes 
and inherited immune deficiency syndromes predispose to lymphomas (Garber and Offit 2005). Thus, 
although most lymphomas are sporadic, the family history of patients with lymphoma (particularly 
young patients) should be clarified, and cases suggestive of inherited susceptibility should be referred 
for genetic consultation. Genetic consultation could be considered, for example, in the case of families 
with three or more close relatives with lymphoma, in families with two first-degree relatives with the 
same uncommon lymphoma subtype, and in families with two young patients (<50 years) with 
lymphoma. The identification of families with lymphoma susceptibility is also important from the 
scientific perspective, because it will enable a better clinical characterization of this entity.  
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Familial clustering of lymphoma is uncommon and guidelines for genetic counseling of families with 
lymphoma susceptibility have not been established. On the basis of the results and the literature 
presented in this work, some factors can, however, be highlighted. When a family with suspected 
lymphoma predisposition is referred to genetic counseling, an important step in the risk assessment is 
to clarify the specific diagnoses of all family members affected by cancer. Details about the 
lymphoma subtype, age at diagnosis and year of diagnosis should be obtained from each family 
member affected by lymphoma, and the reliability of the diagnosis should be evaluated. When 
necessary, revision of the tumor biopsies by a hematopathologist should be considered. When 
evaluating the familial risk, it is important to clarify whether all the lymphoma patients in the family 
are affected by the same lymphoma subtype. 
In genetic counseling of family members, the most likely mode of inheritance in that particular family 
should be communicated, and the risk of healthy family members should be estimated. The latter, 
however, may be challenging, as the penetrance of inherited lymphoma susceptibility is currently not 
known. Although two possible lymphoma susceptibility genes were identified in this study, the 
current data is not sufficient to support the diagnostic screening of NPAT, MLL or KLHDC8B in 
families with lymphoma predisposition. When possible, the families could, however, be offered the 
possibility to participate in scientific research studies. In the future, more data may be available from 
the candidate susceptibility genes, and large-scale sequencing technologies may become routine in the 
field of clinical genetics and provide new opportunities for diagnostic genetic testing.  
The surveillance procedures of at-risk family members in families with lymphoma predisposition 
should be considered individually in each family. Surveillance could include at least the regular 
clinical examination of lymph node regions. In addition, family members could be given information 
about the most common symptoms of lymphoma, such as lymphadenopathy, so that symptomatic 
individuals can seek medical care as early as possible.  
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Conclusions and future prospects 
 
NLPHL and PMBCL are infrequent subtypes of lymphoma and at present their etiological factors are 
unclear. Familial form of NLPHL is very rare, whereas familial clustering of PMBCL has not been 
previously described. The aim of this work was to study the genetic basis of familial clustering of 
these two lymphoma subtypes. The following conclusions can be drawn on the basis of the results of 
this study: 
I) A new Finnish family (Family 1) with four individuals affected by NLPHL was described. 
Germline mutations of the KLHDC8B gene, which have been previously implicated in the familial 
form of cHL, were not detected in Family 1 or in three other previously published NLPHL families. 
Thus, germline mutations of KLHDC8B were excluded as the underlying cause of familial clustering 
of NLPHL.  
II) By utilizing exome sequencing and linkage analysis, a germline deletion c.2437-2438delAG in the 
NPAT gene was found to segregate with NLPHL in Family 1. In addition, a deletion of serine 725 was 
detected in additional HL patients more frequently than in healthy controls. Thus, NPAT was 
identified as a candidate susceptibility gene for NLPHL. Future studies should, however, verify the 
association of NPAT and NLPHL in an independent dataset of cases. In addition, functional studies to 
elucidate the effects of the NPAT deletions could be performed. NPAT mutations were not detected in 
the three previously published foreign NLPHL families and thus, the factors contributing to the onset 
of NLPHL in these families remains unclear.  
III) The familial risk in NLPHL was studied in a population-based cohort of first-degree relatives of 
patients with NLPHL. A high relative risk for NLPHL was observed. An elevated SIR was also found 
for NHL and cHL. These results suggest that familial factors, for example genetic or environmental, 
play a role in the development of NLPHL. Clearly highest relative risk was observed for NLPHL, 
proposing that some of its risk factors may be subtype-specific. However, some risk factors may be 
shared with other lymphoma types. In future studies, the factors contributing to the observed familial 
risk in NLPHL should be clarified. The etiology and risk factors of NLPHL should also be studied 
separately from cHL.  
IV) A Finnish family (Family 2) with three PMBCL-affected siblings and a cousin with DLBCL was 
described in study IV. The combination of exome sequencing and genome-wide linkage analysis 
enabled the identification of the sequence change c.5533C>A (His1845Asn) in MLL which segregated 
with lymphoma in Family 2 and was not found in genetic databases or healthy controls. Thus, 
germline MLL variations may contribute to the onset of familial PMBCL. As other MLL mutations 
were not detected in the screen of the available validation material, future studies are needed for the 
confirmation of our finding. The identification of Family 2 implicates that a familial form of PMBCL 
may exist. The description of this first case enables the identification of additional families, which in 
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